

Wayne D Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8130821/publications.pdf>

Version: 2024-02-01

916
papers

70,708
citations

1893

102
h-index

932

240
g-index

938
all docs

938
docs citations

938
times ranked

66428
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in patterns of youth multiple tobacco and/or e-cigarette product use in the US between 2014 and 2020: a multiple-group latent class analysis. <i>Tobacco Control</i> , 2024, 33, 21-29.	3.2	3
2	Vaping on TikTok: a systematic thematic analysis. <i>Tobacco Control</i> , 2023, 32, 251-254.	3.2	41
3	Efficacy of smokeless tobacco for smoking cessation: a systematic review and meta-analysis. <i>Tobacco Control</i> , 2023, 32, 757-768.	3.2	3
4	Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2023, 53, 3858-3868.	4.5	19
5	A wastewater-based assessment of the impact of a minimum unit price (MUP) on population alcohol consumption in the Northern Territory, Australia. <i>Addiction</i> , 2022, 117, 243-249.	3.3	14
6	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. <i>International Journal of Drug Policy</i> , 2022, 99, 103381.	3.3	75
7	The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. <i>Addiction</i> , 2022, 117, 1510-1517.	3.3	44
8	Prevalence of Adolescent Cannabis Vaping. <i>JAMA Pediatrics</i> , 2022, 176, 42.	6.2	37
9	Why was early therapeutic research on psychedelic drugs abandoned?. <i>Psychological Medicine</i> , 2022, 52, 26-31.	4.5	18
10	Clinical management of cannabis withdrawal. <i>Addiction</i> , 2022, 117, 2075-2095.	3.3	28
11	Is smoking reduction and cessation associated with increased e-cigarette use? Findings from a nationally representative sample of adult smokers in Australia. <i>Addictive Behaviors</i> , 2022, 127, 107217.	3.0	3
12	An age-period-cohort analysis of trends in psychedelic and ecstasy use in the Australian population. <i>Addictive Behaviors</i> , 2022, 127, 107216.	3.0	1
13	Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. <i>Psychopharmacology</i> , 2022, 239, 1509-1519.	3.1	46
14	Did the under-reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased?. <i>Addiction</i> , 2022, 117, 1787-1793.	3.3	4
15	Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies. <i>Pain Medicine</i> , 2022, 23, 1442-1456.	1.9	14
16	Neither the "Devil's Lettuce" nor a "Miracle Cure": The Use of Medical Cannabis in the Care of Children and Youth. <i>Neuroethics</i> , 2022, 15, 1.	2.8	1
17	Perceived access to cannabis and ease of purchasing cannabis in retail stores in Canada immediately before and one year after legalization. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 195-205.	2.1	9
18	The iCannToolkit: a tool to embrace measurement of medicinal and non-medicinal cannabis use across licit, illicit and cross-cultural settings. <i>Addiction</i> , 2022, , .	3.3	3

#	ARTICLE	IF	CITATIONS
19	Tobacco and nicotine use. Nature Reviews Disease Primers, 2022, 8, 19.	30.5	67
20	Long-Term Cannabis Use and Cognitive Reserves and Hippocampal Volume in Midlife. American Journal of Psychiatry, 2022, 179, 362-374.	7.2	33
21	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World Journal of Biological Psychiatry, 2022, 23, 719-742.	2.6	40
22	State-Level Prevalence and Associates of Opioid Dependence in the USA. International Journal of Environmental Research and Public Health, 2022, 19, 3825.	2.6	4
23	A Systematic Review of Trends in US Attitudes toward Cannabis Legalization. Substance Use and Misuse, 2022, 57, 1052-1061.	1.4	25
24	Association between the implementation of tobacco control policies and adolescent vaping in 44 lowerâ€middle, upperâ€middle, and highâ€income countries. Addiction, 2022, 117, 2296-2305.	3.3	7
25	Commentary on Beard <i>et al</i>.: Using survey data to test the hypothesis that eâ€cigarettes are a gateway to cigarette smoking in youth. Addiction, 2022, , .	3.3	1
26	Prevalence and correlates of cannabis use for medicinal reasons â€“ An Australian cross-sectional study. Addictive Behaviors Reports, 2022, 15, 100436.	1.9	5
27	Trends in the use of cannabis products in Canada and the USA, 2018 â€“ 2020: Findings from the International Cannabis Policy Study. International Journal of Drug Policy, 2022, 105, 103716.	3.3	33
28	Ageâ€periodâ€cohort analysis of trends in tobacco smoking, cannabis use, and their coâ€use in the Australian population. Addiction, 2022, 117, 2730-2735.	3.3	8
29	Causal inference with observational data in addiction research. Addiction, 2022, 117, 2736-2744.	3.3	14
30	A critical analysis of Australiaâ€™s ban on the sale of electronic nicotine delivery systems. Neuroethics, 2021, 14, 323-331.	2.8	6
31	Lessons from the public health responses to the US outbreak of vapingâ€related lung injury. Addiction, 2021, 116, 985-993.	3.3	51
32	Treatment rates for alcohol use disorders: a systematic review and metaâ€analysis. Addiction, 2021, 116, 2617-2634.	3.3	70
33	Attitudes towards a hypothetical â€clean nicotineâ€™ product and harm reduction among smokers. International Journal of Drug Policy, 2021, 88, 103020.	3.3	2
34	Reefer Madness: an undeserved classic movie. Addiction, 2021, 116, 963-969.	3.3	2
35	Gateway or common liability? A systematic review and metaâ€analysis of studies of adolescent eâ€cigarette use and future smoking initiation. Addiction, 2021, 116, 743-756.	3.3	108
36	The Misuse of the Precautionary Principle in Justifying Australiaâ€™s Ban on the Sale of Nicotine Vaping Products. Nicotine and Tobacco Research, 2021, 23, 14-20.	2.6	7

#	ARTICLE	IF	CITATIONS
37	A first pass, using preâ€¢history and contemporary history, at understanding why Australia and England have such different policies towards electronic nicotine delivery systems, 1970sâ€¢. 2018. Addiction, 2021, 116, 2577-2585.	3.3	13
38	Youngâ€¢adult compared to adolescent onset of regular cannabis use: A 20â€¢year prospective cohort study of later consequences. Drug and Alcohol Review, 2021, 40, 627-636.	2.1	22
39	The EVALI outbreak makes a strong case for better regulation of all vaporizer products. Addiction, 2021, 116, 999-999.	3.3	1
40	Content analysis of cannabis vaping videos on YouTube. Addiction, 2021, 116, 2443-2453.	3.3	18
41	Do Cannabis Users Reduce Their THC Dosages When Using More Potent Cannabis Products? A Review. Frontiers in Psychiatry, 2021, 12, 630602.	2.6	13
42	New Zealand's failed cannabis legalization referendum â€¢ implications for cannabis policy reform. The Lancet Regional Health - Western Pacific, 2021, 7, 100080.	2.9	5
43	Cannabis use and cannabis use disorder. Nature Reviews Disease Primers, 2021, 7, 16.	30.5	179
44	Personal Correlates of Support for Medical and Recreational Cannabis Legalization in Australia. Frontiers in Psychiatry, 2021, 12, 551661.	2.6	9
45	The â€¢gatewayâ€¢effect of e-cigarettes may be explained by a genetic liability to risk-taking. PLoS Medicine, 2021, 18, e1003554.	8.4	6
46	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. JAMA Network Open, 2021, 4, e213059.	5.9	4
47	Easier patient access to medical cannabis carries risks as well as benefits. Journal of Psychopharmacology, 2021, 35, 1435-1436.	4.0	0
48	Response to Daube & Chapman. Addiction, 2021, 116, 2588-2589.	3.3	0
49	Australian policymakers do not have to choose between protecting youth and allowing smokers to use nicotine vaping products. Addiction, 2021, 116, 2257-2259.	3.3	0
50	Drug Legalization is Not a Masterstroke for Addressing Racial Inequality. American Journal of Bioethics, 2021, 21, 44-46.	0.9	2
51	Was New Zealand's referendum to legalise cannabis premature?. Drug and Alcohol Review, 2021, 40, 882-883.	2.1	2
52	The need for publicly funded research on therapeutic use of psychedelic drugs. World Psychiatry, 2021, 20, 197-198.	10.4	10
53	Effect of Cytisine vs Varenicline on Smoking Cessation. JAMA - Journal of the American Medical Association, 2021, 326, 56.	7.4	50
54	What can we learn from the history of research on psychedelic drugs in the addictions?. Addiction, 2021, 116, 2936-2938.	3.3	2

#	ARTICLE	IF	CITATIONS
55	A systematic review of randomized controlled trials and network meta-analysis of e-cigarettes for smoking cessation. Addictive Behaviors, 2021, 119, 106912.	3.0	50
56	Increased barbiturate deaths: an unintended consequence of increased publicity for methods of do-it-yourself euthanasia?. Addiction, 2021, 116, 3273-3275.	3.3	0
57	Reactions on Twitter towards Australia's proposed import restriction on nicotine vaping products: a thematic analysis. Australian and New Zealand Journal of Public Health, 2021, 45, 543-545.	1.8	2
58	Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology, 2021, 193, 108610.	4.1	39
59	Current and future perspectives for wastewater-based epidemiology as a monitoring tool for pharmaceutical use. Science of the Total Environment, 2021, 789, 148047.	8.0	44
60	Has increased youth e-cigarette use in the USA, between 2014 and 2020, changed conventional smoking behaviors, future intentions to smoke and perceived smoking harms?. Addictive Behaviors, 2021, 123, 107073.	3.0	13
61	Age-related trends in cannabis use in Australia. Findings from a series of large nationally representative surveys. Addictive Behaviors, 2021, 123, 107059.	3.0	2
62	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. British Journal of Clinical Pharmacology, 2021, 87, 3092-3104.	2.4	9
63	Aldous Huxley's Doors of Perception. Addiction, 2021, , .	3.3	1
64	An overview of select cannabis use and supply indicators pre- and post-legalization in Canada. Substance Abuse Treatment, Prevention, and Policy, 2021, 16, 77.	2.2	31
65	Cannabis use and psychosis: a review of reviews. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 403-412.	3.2	123
66	A comparison of trends in wastewater-based data and traditional epidemiological indicators of stimulant consumption in three locations. Addiction, 2020, 115, 462-472.	3.3	13
67	The changing patterns and correlates of population-level polysubstance use in Australian youth: a multi-group latent class analysis of nationally representative samples spanning 12 years. Addiction, 2020, 115, 145-155.	3.3	11
68	Cognitive research on addiction in a changing policy landscape. , 2020, , 321-329.		0
69	Reducing the risks of distortion in cannabis research. Addiction, 2020, 115, 799-801.	3.3	4
70	Addiction 's policy on publishing effectiveness studies of involuntary treatment of addiction and its variants. Addiction, 2020, 115, 1795-1796.	3.3	0
71	Alcohol advertisers may be using social media to encourage parents to drink during COVID-19. Medical Journal of Australia, 2020, 213, 188.	1.7	8
72	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EclinicalMedicine, 2020, 28, 100592.	7.1	16

#	ARTICLE	IF	CITATIONS
73	How many more young Australians say that they would use cannabis if it were legal?. Drug and Alcohol Review, 2020, 39, 768-772.	2.1	1
74	The Effects of Cannabis Use on the Development of Adolescents and Young Adults. Annual Review of Developmental Psychology, 2020, 2, 461-483.	2.9	37
75	Vaping Nicotine Is Far Less Harmful Than Smoking Tobacco. Chest, 2020, 158, 835-836.	0.8	3
76	Availability of substances for use in personal vaporisers on three online cryptomarkets. Drug and Alcohol Dependence, 2020, 217, 108254.	3.2	7
77	Short-Term Effects of State Legalization on Adolescent Cannabis Use May Not Predict Any Longer-Term Effects. American Journal of Public Health, 2020, 110, 1270-1271.	2.7	0
78	Cannabis and COVID-19: Reasons for Concern. Frontiers in Psychiatry, 2020, 11, 601653.	2.6	59
79	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. Public Health in Practice, 2020, 1, 100046.	1.5	1
80	Response to Chapman and Daube. Drug and Alcohol Review, 2020, 39, 422-423.	2.1	1
81	Generational trends in US opioid-overdose deaths. Nature Medicine, 2020, 26, 651-652.	30.7	8
82	A call for greater policy and regulatory coherence for an expanding menu of legal psychoactive substances. Drug and Alcohol Review, 2020, 39, 737-742.	2.1	4
83	Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry, 2020, 19, 179-186.	10.4	159
84	Can wastewater analysis be used as a tool to assess the burden of pain treatment within a population?. Environmental Research, 2020, 188, 109769.	7.5	13
85	Support for the psychosocial, disease and brain disease models of addiction: A survey of treatment providers' attitudes in Australia, the UK, and U.S.. Journal of Substance Abuse Treatment, 2020, 115, 108033.	2.8	9
86	Mitigating and learning from the impact of COVID-19 infection on addictive disorders. Addiction, 2020, 115, 1007-1010.	3.3	204
87	Ensuring access to safe, effective, and affordable cannabis-based medicines. British Journal of Clinical Pharmacology, 2020, 86, 630-634.	2.4	14
88	Does the gateway theory justify a ban on nicotine vaping in Australia?. International Journal of Drug Policy, 2020, 78, 102712.	3.3	7
89	Efficacy of cannabinoids for treating paediatric spasticity in cerebral palsy or traumatic brain injury: what is the evidence?. Developmental Medicine and Child Neurology, 2020, 62, 1007-1007.	2.1	2
90	Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. EclinicalMedicine, 2020, 20, 100294.	7.1	18

#	ARTICLE	IF	CITATIONS
91	Road Safety Risks of Cannabis Use: Sales Need to Fund Research. American Journal of Public Health, 2020, 110, 265-266.	2.7	2
92	Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. International Journal of Drug Policy, 2020, 77, 102698.	3.3	91
93	Disease, wellness, and addiction: A global perspective. , 2020, , 211-224.		1
94	Estimation of the proportion of population cannabis consumption in Australia that is accounted for by daily users using Monte Carlo Simulation. Addiction, 2020, 115, 1182-1186.	3.3	23
95	Cannabinoids for the treatment of mental disorders – Author's reply. Lancet Psychiatry, the, 2020, 7, 127-128.	7.4	0
96	Miscommunication about the causes of the US outbreak of lung diseases in vapers by public health authorities and the media. Drug and Alcohol Review, 2020, 39, 3-6.	2.1	20
97	Could vaping help lower smoking rates in Australia?. Drug and Alcohol Review, 2020, 39, 415-418.	2.1	9
98	Will Legalization and Commercialization of Cannabis Use Increase the Incidence and Prevalence of Psychosis?. JAMA Psychiatry, 2020, 77, 777.	11.0	57
99	Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. European Neuropsychopharmacology, 2020, 36, 169-180.	0.7	81
100	Policy-based evidence on e-cigarette, or vaping product, use-associated lung injury. Drug and Alcohol Review, 2020, 39, 426-427.	2.1	0
101	Adolescent cannabis use disorders. , 2020, , 111-135.		2
102	Commentary on Shi & Liang (2020): Has cannabis legalization increased acute cannabis-related harms?. Addiction, 2020, 115, 1900-1901.	3.3	0
103	Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety, 2020, 29, 1325-1330.	1.9	17
104	What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. Addictive Behaviors, 2020, 109, 106479.	3.0	120
105	The costs and benefits of cannabis control policies. Dialogues in Clinical Neuroscience, 2020, 22, 281-287.	3.7	22
106	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. Pain Medicine, 2019, 20, 758-769.	1.9	9
107	Commentary on Burgard et al . (2019): Wastewater based estimates of the size of illicit markets for psychoactive drugs. Addiction, 2019, 114, 1591-1592.	3.3	1
108	Social, demographic, and economic correlates of food and chemical consumption measured by wastewater-based epidemiology. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21864-21873.	7.1	104

#	ARTICLE	IF	CITATIONS
109	Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. <i>Lancet</i> , The, 2019, 394, 1580-1590.	13.7	224
110	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet</i> , The, 2019, 394, 1668-1684.	13.7	195
111	Strategies to reduce drug-related harm: responding to the evidence base. <i>Lancet</i> , The, 2019, 394, 1490-1493.	13.7	15
112	Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107533.	3.2	23
113	Alcohol consumption and consequences in adolescents in 68 low and middle-income countries – a multi-country comparison of risks by sex. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107520.	3.2	16
114	Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , the, 2019, 6, 995-1010.	7.4	306
115	Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. <i>International Journal of Drug Policy</i> , 2019, 73, 96-99.	3.3	3
116	Cannabinoids for the treatment of spasticity. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 631-638.	2.1	19
117	Cannabis use and mental health: risks and benefits. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 1-3.	3.2	19
118	Traffic fatalities within US states that have legalized recreational cannabis sales and their neighbours. <i>Addiction</i> , 2019, 114, 847-856.	3.3	57
119	The Indian Hemp Drugs Commission 1893–1894. <i>Addiction</i> , 2019, 114, 1679-1682.	3.3	5
120	A major expansion of opioid agonist treatment is needed to reduce overdose deaths in the USA. <i>Lancet Public Health</i> , The, 2019, 4, e77-e78.	10.0	10
121	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	1.9	12
122	Correlates of electronic cigarette use in the general population and among smokers in Australia – Findings from a nationally representative survey. <i>Addictive Behaviors</i> , 2019, 95, 6-10.	3.0	19
123	A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2019, 101, 365-369.	8.1	11
124	What Have Been the Public Health Impacts of Cannabis Legalisation in the USA? A Review of Evidence on Adverse and Beneficial Effects. <i>Current Addiction Reports</i> , 2019, 6, 418-428.	3.4	29
125	Predicting vaping uptake, vaping frequency and ongoing vaping among daily smokers using longitudinal data from the International Tobacco Control (ITC) Four Country Surveys. <i>Addiction</i> , 2019, 114, 61-70.	3.3	13
126	A National Wastewater Monitoring Program for a better understanding of public health: A case study using the Australian Census. <i>Environment International</i> , 2019, 122, 400-411.	10.0	59

#	ARTICLE	IF	CITATIONS
127	The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. <i>Addiction</i> , 2019, 114, 923-933.	3.3	11
128	Longitudinal patterns of amphetamine use from adolescence to adulthood: A latent class analysis of a 20-year prospective study of Australians. <i>Drug and Alcohol Dependence</i> , 2019, 194, 121-127.	3.2	7
129	Non-medical use of pharmaceutical opioids with and without other illicit substances in Australia: Prevalence and correlates. <i>Drug and Alcohol Review</i> , 2019, 38, 151-158.	2.1	6
130	Finding acceptable ways to fund research on e-cigarettes. <i>Addiction</i> , 2019, 114, 375-376.	3.3	0
131	The Age of Onset of Alcohol Use Disorders. , 2019, , 169-182.		2
132	Capacity, control and responsibility in Parkinson's disease patients with impulse control disorders: Views of neurological and psychiatric experts. <i>International Journal of Law and Psychiatry</i> , 2019, 65, 101-113.	0.9	2
133	Epidemiology of Substance Use Internationally. <i>Advances in Prevention Science</i> , 2019, , 19-36.	0.3	4
134	The Age of Onset of Substance Use Disorders. , 2019, , 149-167.		6
135	It is premature to expand access to medicinal cannabis in hopes of solving the US opioid crisis. <i>Addiction</i> , 2018, 113, 987-988.	3.3	37
136	Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 741-753.	1.9	138
137	Familial alcohol supply, adolescent drinking and early alcohol onset in 45 low and middle income countries. <i>Addictive Behaviors</i> , 2018, 84, 178-185.	3.0	11
138	Thresholds for safer alcohol use might need lowering. <i>Lancet</i> , The, 2018, 391, 1460-1461.	13.7	15
139	Formulating more consistent public health policies towards cannabis and tobacco. <i>Addiction</i> , 2018, 113, 608-609.	3.3	2
140	The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 8.	4.2	116
141	Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology. <i>Addiction</i> , 2018, 113, 1127-1136.	3.3	62
142	Association between purity of drug seizures and illicit drug loads measured in wastewater in a South East Queensland catchment over a six year period. <i>Science of the Total Environment</i> , 2018, 635, 779-783.	8.0	20
143	Accurate identification of opioid overdose deaths using coronial data. <i>Forensic Science International</i> , 2018, 287, 40-46.	2.2	13
144	The diverging trajectories of cannabis and tobacco policies in the United States: reasons and possible implications. <i>Addiction</i> , 2018, 113, 595-601.	3.3	28

#	ARTICLE	IF	CITATIONS
145	Do Neurobiological Understandings of Smoking Influence Quitting Self-Efficacy or Treatment Intentions?. Nicotine and Tobacco Research, 2018, 20, 827-835.	2.6	7
146	The need to exercise caution in accepting addiction as a reason for performing euthanasia. Addiction, 2018, 113, 1178-1180.	3.3	7
147	Socioeconomic differentials in cannabis use trends in Australia. Addiction, 2018, 113, 454-461.	3.3	13
148	The future of the international drug control system and national drug prohibitions. Addiction, 2018, 113, 1210-1223.	3.3	31
149	Drug and alcohol treatment providers'™ views about the disease model of addiction and its impact on clinical practice: A systematic review. Drug and Alcohol Review, 2018, 37, 697-720.	2.1	63
150	Ice Rushes™, Data Shadows and Methamphetamine Use in Rural Towns: Wastewater Analysis. Current Issues in Criminal Justice, 2018, 29, 195-208.	1.4	2
151	Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use. BMC Public Health, 2018, 18, 1270.	2.9	21
152	Can automated content analysis be used to assess and improve the use of evidence in mental health policy? A systematic review. Systematic Reviews, 2018, 7, 194.	5.3	7
153	What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. International Review of Psychiatry, 2018, 30, 91-106.	2.8	25
154	Has the Legalisation of Medical and Recreational Cannabis Use in the USA Affected the Prevalence of Cannabis Use and Cannabis Use Disorders?. Current Addiction Reports, 2018, 5, 403-417.	3.4	51
155	Ethical Guidelines for Genetic Research on Alcohol Addiction and Its Applications. Kennedy Institute of Ethics Journal, 2018, 28, 1-22.	0.5	1
156	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry, the, 2018, 5, 987-1012.	7.4	885
157	Cannabis use and non-cancer chronic pain – Authors' reply. Lancet Public Health, The, 2018, 3, e469.	10.0	1
158	The challenges in providing safe, effective, affordable cannabis-based medicines for unapproved indications. Medical Journal of Australia, 2018, 209, 209-210.	1.7	1
159	Minimizing the adverse public health effects of cannabis legalization. Cmaj, 2018, 190, E1031-E1032.	2.0	11
160	Reasons for ambivalence about accepting addiction as a reason for performing euthanasia. Addiction, 2018, 113, 1186-1187.	3.3	1
161	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain, 2018, 159, 1932-1954.	4.2	321
162	Prisoners and risk of injury after release. Lancet Public Health, The, 2018, 3, e209-e210.	10.0	1

#	ARTICLE	IF	CITATIONS
163	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health, The</i> , 2018, 3, e341-e350.	10.0	172
164	Regulating e-cigarettes in Australia: implications for tobacco use by young people. <i>Medical Journal of Australia</i> , 2018, 208, 415-415.	1.7	0
165	Reducing the opioid overdose death toll in North America. <i>PLoS Medicine</i> , 2018, 15, e1002626.	8.4	15
166	Implications of treatment providers' varying conceptions of the disease model of addiction: A response. <i>Drug and Alcohol Review</i> , 2018, 37, 729-730.	2.1	4
167	Amphetamine use in the fourth decade of life: Social profiles from a population-based Australian cohort. <i>Drug and Alcohol Review</i> , 2018, 37, 743-751.	2.1	4
168	Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. <i>Addiction</i> , 2018, 113, 1811-1825.	3.3	43
169	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
170	Imperfect international treaties interpreted flexibly are likely to be better than no treaties. <i>Addiction</i> , 2018, 113, 1230-1230.	3.3	0
171	The need for more consistent evidential standards in cannabis policy evaluations. <i>Addiction</i> , 2018, 113, 1553-1554.	3.3	2
172	Gateway Drug Use. , 2018, , 1530-1538.		0
173	Crystalline methamphetamine use and methamphetamine-related harms in Australia. <i>Drug and Alcohol Review</i> , 2017, 36, 160-170.	2.1	126
174	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	1.9	39
175	Neuroscience in gambling policy and treatment: an interdisciplinary perspective. <i>Lancet Psychiatry,the</i> , 2017, 4, 501-506.	7.4	14
176	Substance Use Terminology. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 769.	7.4	0
177	Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. <i>Lancet Psychiatry,the</i> , 2017, 4, 265-266.	7.4	4
178	Disease or Developmental Disorder: Competing Perspectives on the Neuroscience of Addiction. <i>Neuroethics</i> , 2017, 10, 103-110.	2.8	18
179	A qualitative study of overweight and obese Australians' views of food addiction. <i>Appetite</i> , 2017, 115, 62-70.	3.7	17
180	Socioeconomic status and susceptibility to alcohol-related harm. <i>Lancet Public Health, The</i> , 2017, 2, e250-e251.	10.0	12

#	ARTICLE	IF	CITATIONS
181	User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate. Drug and Alcohol Dependence, 2017, 178, 32-38.	3.2	71
182	The Use of Cannabinoids in Treating Dementia. Current Neurology and Neuroscience Reports, 2017, 17, 56.	4.2	19
183	Medicalisation, smoking and e-cigarettes: evidence and implications. Tobacco Control, 2017, 26, e134-e139.	3.2	10
184	Value for money in reducing opioid-related deaths. Lancet Public Health, The, 2017, 2, e124-e125.	10.0	5
185	Has Marijuana Legalization Increased Marijuana Use Among US Youth?. JAMA Pediatrics, 2017, 171, 116.	6.2	8
186	A prospectus for ethical analysis of ageing individuals' responsibility to prevent cognitive decline. Bioethics, 2017, 31, 657-665.	1.4	4
187	Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug and Alcohol Dependence, 2017, 179, 291-298.	3.2	142
188	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, 1277-1277.	2.7	25
189	Mental disorders in offspring of parents who have been homeless. Lancet Public Health, The, 2017, 2, e530-e531.	10.0	1
190	Fischer et al. Respond. American Journal of Public Health, 2017, 107, e26-e27.	2.7	1
191	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, e1-e12.	2.7	295
192	Framing Tobacco Dependence as a "Brain Disease": Implications for Policy and Practice. Nicotine and Tobacco Research, 2017, 19, 774-780.	2.6	14
193	Parental supply of alcohol and adolescent drinking: a multilevel analysis of nationally representative data. BMC Public Health, 2017, 17, 560.	2.9	24
194	An analysis of policy success and failure in formal evaluations of Australia's national mental health strategy (1992-2012). BMC Health Services Research, 2017, 17, 374.	2.2	11
195	Predictors of retention in a randomised trial of smoking cessation in low-socioeconomic status Australian smokers. Addictive Behaviors, 2017, 64, 13-20.	3.0	22
196	Alcohol and cannabis: Comparing their adverse health effects and regulatory regimes. International Journal of Drug Policy, 2017, 42, 57-62.	3.3	46
197	Lee Robins' studies of heroin use among US Vietnam veterans. Addiction, 2017, 112, 176-180.	3.3	13
198	Understanding the true economic impact of self-harming behaviour. Lancet Psychiatry, the, 2017, 4, 900-901.	7.4	24

#	ARTICLE	IF	CITATIONS
199	The Global Epidemiology and Disease Burden of Cannabis Use and Dependence. , 2017, , 89-100.		11
200	Illicit Drugs: Patterns of Use, Dependence, and Contribution to Disease Burden in Developed Countries. , 2017, , 134-145.		2
201	Reducing alcoholâ€related violence and other harm in Australia. Medical Journal of Australia, 2017, 206, 111-112.	1.7	2
202	International Aspects of Cannabis Use and Misuse: the Australian Perspective. , 2017, , 101-109.		1
203	Smoking and finances: baseline characteristics of low income daily smokers in the FISCALS cohort. International Journal for Equity in Health, 2017, 16, 157.	3.5	4
204	How do we define the policy impact of public health research? A systematic review. Health Research Policy and Systems, 2017, 15, 84.	2.8	49
205	Looking to the future: Clinical and policy implications of the brain disease model of addiction. , 2017, , .		0
206	Concussion, neuroethics, and sport: Policies of the past do not suffice for the future. , 2017, , .		0
207	Trends in methamphetamine residues in wastewater in metropolitan and regional cities in southâ€east Queensland, 2009â€2015. Medical Journal of Australia, 2016, 204, 151-152.	1.7	18
208	Estimating the number of regular and dependent methamphetamine users in Australia, 2002â€2014. Medical Journal of Australia, 2016, 205, 426-426.	1.7	1
209	Estimating the number of regular and dependent methamphetamine users in Australia, 2002â€2014. Medical Journal of Australia, 2016, 204, 153-153.	1.7	78
210	How Much Can the USA Reduce Health Care Costs by Reducing Smoking?. PLoS Medicine, 2016, 13, e1002021.	8.4	17
211	The is and ought of the Ethics of Neuroenhancement: Mind the Gap. Frontiers in Psychology, 2016, 6, 1998.	2.1	15
212	Australian University Studentsâ€™ Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers. Frontiers in Psychology, 2016, 7, 277.	2.1	44
213	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. Pain, 2016, 157, 1489-1498.	4.2	43
214	Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction, 2016, 111, 1764-1773.	3.3	270
215	Realising the technological promise of smartphones in addiction research and treatment: An ethical review. International Journal of Drug Policy, 2016, 36, 47-57.	3.3	54
216	Assessing the place of neurobiological explanations in accounts of a family member's addiction. Drug and Alcohol Review, 2016, 35, 461-469.	2.1	9

#	ARTICLE	IF	CITATIONS
217	Does parental monitoring and disapproval explain variations in alcohol use among adolescents from different countries of birth?. <i>Drug and Alcohol Review</i> , 2016, 35, 741-749.	2.1	11
218	Management of impulse control disorders in Parkinson's disease. <i>International Psychogeriatrics</i> , 2016, 28, 1597-1614.	1.0	16
219	Adolescent Predictors of a Typology of DSM-5 Alcohol Use Disorder Symptoms in Young Adults Derived by Latent Class Analysis Using Data From an Australian Cohort Study. <i>Journal of Studies on Alcohol and Drugs</i> , 2016, 77, 757-765.	1.0	9
220	How Did Youth Mental Health Make It Onto Australia's 2011 Federal Policy Agenda?. <i>SAGE Open</i> , 2016, 6, 215824401668085.	1.7	10
221	Scepticism and hope in a complex predicament: People with addictions deliberate about neuroscience. <i>International Journal of Drug Policy</i> , 2016, 32, 34-43.	3.3	16
222	Which adolescents develop persistent substance dependence in adulthood? Using population-representative longitudinal data to inform universal risk assessment. <i>Psychological Medicine</i> , 2016, 46, 877-889.	4.5	67
223	Refining the excretion factors of methadone and codeine for wastewater analysis – Combining data from pharmacokinetic and wastewater studies. <i>Environment International</i> , 2016, 94, 307-314.	10.0	49
224	Spatial variations in the consumption of illicit stimulant drugs across Australia: A nationwide application of wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2016, 568, 810-818.	8.0	84
225	Cannabis use and cannabis use disorders. <i>Lancet Psychiatry</i> , 2016, 3, 911-912.	7.4	4
226	Technical Note: On modelling thermo-chemical degradation of poly(lactic acid). <i>Polymer Degradation and Stability</i> , 2016, 134, 19-21.	5.8	8
227	The challenge of reducing smoking in people with serious mental illness. <i>Lancet Respiratory Medicine</i> , 2016, 4, 835-844.	10.7	44
228	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases</i> , 2016, 16, 1385-1398.	9.1	223
229	Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. <i>Lancet Psychiatry</i> , 2016, 3, 900-906.	7.4	66
230	Commentary on Ogeil et al . (2016): Explaining increased alcohol-related harm and stable per capita consumption in Australia. <i>Addiction</i> , 2016, 111, 635-636.	3.3	3
231	Commentary on Imtiaz et al . (2016): The burden of disease attributable to cannabis – implications for policy. <i>Addiction</i> , 2016, 111, 663-664.	3.3	1
232	Cocaine, MDMA and methamphetamine residues in wastewater: Consumption trends (2009–2015) in South East Queensland, Australia. <i>Science of the Total Environment</i> , 2016, 568, 803-809.	8.0	61
233	Assessing the place of nicotine vaporisers in tobacco control. <i>Tobacco Control</i> , 2016, 25, e1-e2.	3.2	4
234	Trend in alcohol use in Australia over 13 years: has there been a trend reversal?. <i>BMC Public Health</i> , 2016, 16, 1070.	2.9	18

#	ARTICLE	IF	CITATIONS
235	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. Australian Health Review, 2016, 40, 490.	1.1	8
236	Lucas Richert,Conservatism, Consumer Choice and the Food and Drug Administration during the Reagan Era. Social History of Medicine, 2016, 29, 202-203.	0.2	0
237	Prevalence and Correlates of Suicidal Thoughts and Suicide Attempts in People Prescribed Pharmaceutical Opioids for Chronic Pain. Clinical Journal of Pain, 2016, 32, 292-301.	1.9	39
238	The Neurobiology of "Food Addiction" and Its Implications for Obesity Treatment and Policy. Annual Review of Nutrition, 2016, 36, 105-128.	10.1	151
239	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. Drug and Alcohol Dependence, 2016, 162, 79-87.	3.2	40
240	Parental supply of alcohol to Australian minors: an analysis of six nationally representative surveys spanning 15 years. BMC Public Health, 2016, 16, 325.	2.9	34
241	Rural and Urban Differences in Adolescent Alcohol Use, Alcohol Supply, and Parental Drinking. Journal of Rural Health, 2016, 32, 280-286.	2.9	38
242	Challenges and opportunities in using wastewater analysis to measure drug use in a small prison facility. Drug and Alcohol Review, 2016, 35, 138-147.	2.1	27
243	A qualitative study of smokers' views on brain-based explanations of tobacco dependence. International Journal of Drug Policy, 2016, 29, 41-48.	3.3	10
244	Monitoring temporal changes in use of two cathinones in a large urban catchment in Queensland, Australia. Science of the Total Environment, 2016, 545-546, 250-255.	8.0	34
245	Regional versus urban differences in teenage alcohol use: Does parental disapproval account for these differences?. Australian Journal of Rural Health, 2016, 24, 3-8.	1.5	11
246	Prevention, early intervention, harm reduction, and treatment of substance use in young people. Lancet Psychiatry,the, 2016, 3, 280-296.	7.4	296
247	The increasing global health priority of substance use in young people. Lancet Psychiatry,the, 2016, 3, 251-264.	7.4	378
248	Why young people's substance use matters for global health. Lancet Psychiatry,the, 2016, 3, 265-279.	7.4	230
249	Long-term Marijuana Use and Cognitive Impairment in Middle Age. JAMA Internal Medicine, 2016, 176, 362.	5.1	12
250	Alcohol use disorders. Lancet, The, 2016, 387, 988-998.	13.7	277
251	Illicit Drug Dependence. , 2016, , 109-125.		10
252	Establishing and Governing e-Mental Health Care in Australia: A Systematic Review of Challenges and A Call For Policy-Focussed Research. Journal of Medical Internet Research, 2016, 18, e10.	4.3	89

#	ARTICLE	IF	CITATIONS
253	Gateway Drug Use. , 2016, , 1-9.		0
254	Ethical issues raised by a ban on the sale of electronic nicotine devices. Addiction, 2015, 110, 1061-1067.	3.3	40
255	Getting to grips with the cannabis problem: the evolving contributions and impact of Griffith Edwards. Addiction, 2015, 110, 36-39.	3.3	1
256	Ethical, Social and Clinical Challenges in using Deep Brain Stimulation to Treat Addiction and Other Impulsive and Compulsive Disorders. Jahrbuch F�r Wissenschaft Und Ethik, 2015, 19, 163-188.	0.2	0
257	Researchers���� perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey. Scientific Reports, 2015, 5, 10618.	3.3	31
258	Does the social context of early alcohol use affect risky drinking in adolescents? Prospective cohort study. BMC Public Health, 2015, 15, 1137.	2.9	17
259	An analysis of policy levers used to implement mental health reform in Australia 1992-2012. BMC Health Services Research, 2015, 15, 479.	2.2	13
260	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. International Journal of Clinical Practice, 2015, 69, 1366-1376.	1.7	7
261	Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiology and Drug Safety, 2015, 24, 628-636.	1.9	34
262	Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Medical Journal of Australia, 2015, 203, 299-299.	1.7	63
263	Why Don��t Smokers Want Help to Quit? A Qualitative Study of Smokers���� Attitudes towards Assisted vs. Unassisted Quitting. International Journal of Environmental Research and Public Health, 2015, 12, 6591-6607.	2.6	65
264	Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation. Australian and New Zealand Journal of Psychiatry, 2015, 49, 106-117.	2.3	50
265	Possible causes and consequences of reduced perceptions of the risks of using cannabis. Clinical Toxicology, 2015, 53, 141-142.	1.9	6
266	An Ethical Reevaluation: Where Are the Voices of Those With Anorexia Nervosa and Their Families?. AJOB Neuroscience, 2015, 6, 73-74.	1.1	0
267	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. Pain Medicine, 2015, 16, 1745-1758.	1.9	78
268	Vote of thanks to Professor Tom Babor. Addiction, 2015, 110, 1060-1060.	3.3	0
269	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 2015, 16, 356-366.	1.9	102
270	Nuances in the ethical regulation of electronic nicotine delivery systems. Addiction, 2015, 110, 1074-1075.	3.3	2

#	ARTICLE	IF	CITATIONS
271	Media and evidence-informed policy development: the case of mental health in Australia. Contemporary Social Science, 2015, 10, 160-170.	1.9	12
272	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. Lancet Psychiatry,the, 2015, 2, 314-322.	7.4	55
273	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 2015, 147, 144-150.	3.2	97
274	Systematic and Day-to-Day Effects of Chemical-Derived Population Estimates on Wastewater-Based Drug Epidemiology. Environmental Science & Technology, 2015, 49, 999-1008.	10.0	65
275	Profiling Hello Sunday Morning: Who are the participants?. International Journal of Drug Policy, 2015, 26, 214-216.	3.3	28
276	The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?. Lancet Psychiatry,the, 2015, 2, 105-110.	7.4	158
277	A longitudinal study of the association of adolescent polydrug use, alcohol use and high school non-completion. Addiction, 2015, 110, 627-635.	3.3	130
278	Repeated Head Injuries in Australia's Collision Sports Highlight Ethical and Evidential Gaps in Concussion Management Policies. Neuroethics, 2015, 8, 39-45.	2.8	5
279	A licence to vape: Is it time to trial of a nicotine licensing scheme to allow Australian adults controlled access to electronic cigarettes devices and refill solutions containing nicotine?. International Journal of Drug Policy, 2015, 26, 548-553.	3.3	12
280	Rethinking cigarette smoking, cannabis use, and psychosis. Lancet Psychiatry,the, 2015, 2, 581-582.	7.4	9
281	Heroin-assisted treatment: has a controversial treatment come of age?. British Journal of Psychiatry, 2015, 207, 3-4.	2.8	15
282	Tobacco harm reduction in people with serious mental illnesses. Lancet Psychiatry,the, 2015, 2, 485-487.	7.4	17
283	The brain disease model of addiction: challenging or reinforcing stigma? "Authors' reply. Lancet Psychiatry,the, 2015, 2, 292.	7.4	6
284	High potency cannabis. BMJ, The, 2015, 350, h1205-h1205.	6.0	39
285	Challenges in minimizing the adverse effects of cannabis use after legalization. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 1013-1015.	3.1	9
286	Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clinical Pharmacology and Therapeutics, 2015, 97, 607-615.	4.7	141
287	The Pain and Opioids IN Treatment study. Pain, 2015, 156, 231-242.	4.2	104
288	Alcohol burden in low-income and middle-income countries. Lancet, The, 2015, 386, 1922-1924.	13.7	24

#	ARTICLE	IF	CITATIONS
289	Excess mortality among opioid-using patients treated with oral naltrexone in Australia. Drug and Alcohol Review, 2015, 34, 90-96.	2.1	18
290	Brain disease model of addiction: misplaced priorities?. Lancet Psychiatry, the, 2015, 2, 867.	7.4	22
291	What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?. Addiction, 2015, 110, 19-35.	3.3	440
292	Mobile Phones in Research and Treatment: Ethical Guidelines and Future Directions. JMIR MHealth and UHealth, 2015, 3, e95.	3.7	103
293	Ethical Issues in the Neuroprediction of Addiction Risk and Treatment Response. , 2015, , 1025-1044.		1
294	What Is Addiction Neuroethics?. , 2015, , 995-998.		1
295	U.S. Policy Responses to Calls for the Medical Use of Cannabis. Yale Journal of Biology and Medicine, 2015, 88, 257-64.	0.2	11
296	E-cigarettes and the law in Australia. Australian Family Physician, 2015, 44, 415-8.	0.5	34
297	Food Addiction and Its Impact on Weight-Based Stigma and the Treatment of Obese Individuals in the U.S. and Australia. Nutrients, 2014, 6, 5312-5326.	4.1	68
298	Illicit Drugs. , 2014, , .		0
299	Stimulant and other substance use disorders in schizophrenia: Prevalence, correlates and impacts in a population sample. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1036-1047.	2.3	49
300	Reaching "An Audience That You Would Never Dream of Speaking To" Influential Public Health Researchers' Views on the Role of News Media in Influencing Policy and Public Understanding. Journal of Health Communication, 2014, 19, 260-273.	2.4	31
301	Should doctors prescribe cannabinoids?. BMJ, The, 2014, 348, g2737-g2737.	6.0	15
302	Afghanistan has a sizeable problem with opioid use. The Lancet Global Health, 2014, 2, e557-e558.	6.3	3
303	A randomized clinical trial of a financial education intervention with nicotine replacement therapy (<scp>NRT</scp>) for low socio-economic status <scp>A</scp>ustralian smokers: a study protocol. Addiction, 2014, 109, 1602-1611.	3.3	13
304	The Global Burden of Disease projects: What have we learned about illicit drug use and dependence and their contribution to the global burden of disease?. Drug and Alcohol Review, 2014, 33, 4-12.	2.1	75
305	Patterns of tobacco smoking among illicit drug users in <scp>A</scp>ustralia 2001-2010. Drug and Alcohol Review, 2014, 33, 534-539.	2.1	7
306	Collecting real-time data from substance users raises unique legal and ethical issues: reply to <scp>K</scp>untsche & <scp>L</scp>abhart. Addiction, 2014, 109, 1760-1760.	3.3	6

#	ARTICLE	IF	CITATIONS
307	Response to <sc>H</sc>ser <i>et al</i>. (2014): The necessity for more and better data on the global epidemiology of opioid dependence. <i>Addiction</i> , 2014, 109, 1335-1337.	3.3	3
308	Compulsory treatment of addiction in the patient's best interests: More rigorous evaluations are essential. <i>Drug and Alcohol Review</i> , 2014, 33, 268-271.	2.1	15
309	Public attitudes in <sc>A</sc>ustralia towards the claim that addiction is a (brain) disease. <i>Drug and Alcohol Review</i> , 2014, 33, 272-279.	2.1	21
310	Commentary on <sc>O</sc>rt <i>et al</i>. (2014): What next to deliver on the promise of large scale sewage-based drug epidemiology?. <i>Addiction</i> , 2014, 109, 1353-1354.	3.3	14
311	How is acceptance of the brain disease model of addiction related to Australians' attitudes towards addicted individuals and treatments for addiction?. <i>BMC Psychiatry</i> , 2014, 14, 373.	2.6	43
312	Alienation and Authenticity in Parkinson's Disease and Its Treatment. <i>AJOB Neuroscience</i> , 2014, 5, 54-56.	1.1	2
313	Estimated verbal IQ and the odds of problem gambling: a population-based study. <i>Psychological Medicine</i> , 2014, 44, 1739-1749.	4.5	15
314	Causes of death in a cohort treated for opioid dependence between 1985 and 2005. <i>Addiction</i> , 2014, 109, 90-99.	3.3	92
315	<i>Addiction</i> editors respond to Mr Leverton. <i>Addiction</i> , 2014, 109, 1209-1211.	3.3	1
316	The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. <i>Drug and Alcohol Dependence</i> , 2014, 137, 36-47.	3.2	126
317	'If you're healthy you don't need drugs' Public attitudes towards 'brain doping' in the classroom and 'legalised doping' in sport. <i>Performance Enhancement and Health</i> , 2014, 3, 20-25.	1.6	9
318	Sewage epidemiology and illicit drug research: The development of ethical research guidelines. <i>Science of the Total Environment</i> , 2014, 472, 550-555.	8.0	62
319	The adverse health effects of chronic cannabis use. <i>Drug Testing and Analysis</i> , 2014, 6, 39-45.	2.6	288
320	Conflicts of Interest in Recommendations to Use Computerized Neuropsychological Tests to Manage Concussion in Professional Football Codes. <i>Neuroethics</i> , 2014, 7, 63-74.	2.8	10
321	Public Understandings of Addiction: Where do Neurobiological Explanations Fit?. <i>Neuroethics</i> , 2014, 7, 51-62.	2.8	15
322	The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. <i>Addiction</i> , 2014, 109, 1320-1333.	3.3	308
323	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. <i>Drug and Alcohol Review</i> , 2014, 33, 115-128.	2.1	41
324	Young adult sequelae of adolescent cannabis use: an integrative analysis. <i>Lancet Psychiatry</i> , 2014, 1, 286-293.	7.4	354

#	ARTICLE	IF	CITATIONS
325	<scp>R</scp>obin <scp>R</scp>oom and cannabis policy: Dangerous comparisons. Drug and Alcohol Review, 2014, 33, 612-616.	2.1	4
326	Monitoring substance use in prisons: Assessing the potential value of wastewater analysis. Science and Justice - Journal of the Forensic Science Society, 2014, 54, 338-345.	2.1	19
327	Should Australia reconsider its ban on the sale of electronic nicotine delivery systems?. Lancet Respiratory Medicine,the, 2014, 2, 602-604.	10.7	7
328	Factors influencing womenâ€™s decisions to drink alcohol during pregnancy: findings of a qualitative study with implications for health communication. BMC Pregnancy and Childbirth, 2014, 14, 246.	2.4	50
329	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 2014, 15, 17.	2.4	39
330	Control and Responsibility in Addicted Individuals: What do Addiction Neuroscientists and Clinicians Think?. Neuroethics, 2014, 7, 205-214.	2.8	14
331	A Bio-Social and Ethical Framework for Understanding Fetal Alcohol Spectrum Disorders. Neuroethics, 2014, 7, 337-344.	2.8	10
332	Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry, 2014, 14, 74.	2.6	29
333	Views of Addiction Neuroscientists and Clinicians on the Clinical Impact of a â€˜Brain Disease Model of Addictionâ€™. Neuroethics, 2014, 7, 19-27.	2.8	30
334	Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis. British Journal of Psychiatry, 2014, 204, 448-453.	2.8	26
335	Estimating treatment rates for mental disorders in Australia. Australian Health Review, 2014, 38, 80.	1.1	145
336	Generational Increase in Young Womenâ€™s Drinking. JAMA Psychiatry, 2014, 71, 952.	11.0	24
337	Australian University Studentsâ€™ Attitudes Towards the Acceptability and Regulation of Pharmaceuticals to Improve Academic Performance. Neuroethics, 2013, 6, 197-205.	2.8	57
338	Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet, The, 2013, 382, 1564-1574.	13.7	668
339	Ethical implications of research on craving. Addictive Behaviors, 2013, 38, 1593-1599.	3.0	7
340	British cannabis policy: an enduring and uneasy compromise. Lancet, The, 2013, 381, 1351.	13.7	1
341	<scp>A</scp>ustralian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: Perceived patterns of use, efficacy and safety. Drug and Alcohol Review, 2013, 32, 295-302.	2.1	56
342	Error and Bias in the Evaluation of Prescription Opioid Misuse: Should the FDA Regulate Clinical Assessment Tools?. Pain Medicine, 2013, 14, 982-987.	1.9	5

#	ARTICLE	IF	CITATIONS
343	Anticipating possible policy uses of addiction neuroscience research. <i>Drugs: Education, Prevention and Policy</i> , 2013, 20, 249-257.	1.3	6
344	Dealing with Ennui: To What Extent Is "Cognitive Enhancement" a Form of Self-Medication for Symptoms of Depression?. <i>AJOB Neuroscience</i> , 2013, 4, 17-17.	1.1	4
345	Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semi-rural and a vacation area. <i>Addiction</i> , 2013, 108, 556-565.	3.3	101
346	Differences in associations between cannabis and stimulant disorders in first admission psychosis. <i>Schizophrenia Research</i> , 2013, 147, 216-222.	2.0	23
347	The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. <i>Addiction</i> , 2013, 108, 124-133.	3.3	183
348	Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival. <i>Drug and Alcohol Review</i> , 2013, 32, 594-602.	2.1	103
349	Navigating the enhancement landscape. <i>EMBO Reports</i> , 2013, 14, 123-128.	4.5	25
350	Cannabis Use and the Development and Maintenance of Psychosis. , 2013, , 517-524.		1
351	National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story. <i>Australasian Psychiatry</i> , 2013, 21, 442-445.	0.7	8
352	Is the socioeconomic gap in childhood exposure to secondhand smoke widening or narrowing?. <i>Tobacco Control</i> , 2013, 22, 344-348.	3.2	30
353	What does "acceptance" mean? Public reflections on the idea that addiction is a brain disease. <i>BioSocieties</i> , 2013, 8, 491-506.	1.3	20
354	Public Attitudes Toward the Treatment of Nicotine Addiction. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1617-1622.	2.6	9
355	Response to Raitan. <i>Addiction</i> , 2013, 108, 650-651.	3.3	0
356	Who is responsible for the public's health? The role of the alcohol industry in the WHO global strategy to reduce the harmful use of alcohol. <i>Addiction</i> , 2013, 108, 2045-2047.	3.3	31
357	Smoking and mental health in young women " challenges in interpretation: a reply. <i>Psychological Medicine</i> , 2013, 43, 445-447.	4.5	0
358	Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. <i>Drug and Alcohol Review</i> , 2013, 32, n/a-n/a.	2.1	12
359	Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2013, 37, 132-138.	1.8	23
360	Managing Suicide Risk in Experimental Treatments of Treatment-Resistant Depression. <i>AJOB Neuroscience</i> , 2013, 4, 38-39.	1.1	2

#	ARTICLE	IF	CITATIONS
361	Constraints on Regulatory Options for Putatively Cognitive Enhancing Drugs. American Journal of Bioethics, 2013, 13, 35-37.	0.9	6
362	Justice and Equity in Trials of Deep Brain Stimulation for the Treatment of Addiction and Overeating. AJOB Neuroscience, 2013, 4, 54-56.	1.1	0
363	The persistence of adolescent binge drinking into adulthood: findings from a 15-year prospective cohort study. BMJ Open, 2013, 3, e003015.	1.9	61
364	Drug Decriminalization and Legalization. , 2013, , 689-696.		0
365	Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Medical Journal of Australia, 2013, 198, 80-81.	1.7	32
366	Did the elimination of lead from petrol reduce crime in the USA in the 1990s?. F1000Research, 2013, 2, 156.	1.6	2
367	Public Views on Food Addiction and Obesity: Implications for Policy and Treatment. PLoS ONE, 2013, 8, e74836.	2.5	50
368	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. PLoS ONE, 2013, 8, e76635.	2.5	235
369	Polysubstance Use in Cannabis Users Referred for Treatment: Drug Use Profiles, Psychiatric Comorbidity and Cannabis-Related Beliefs. Frontiers in Psychiatry, 2013, 4, 79.	2.6	66
370	Advocates need to show compulsory treatment of opioid dependence is effective, safe and ethical. Bulletin of the World Health Organization, 2013, 91, 146-146.	3.3	9
371	Ethical Issues in the Treatment of Drug Dependence. , 2013, , 611-620.		0
372	Addiction Neuroethics. , 2013, , 541-549.		0
373	Alcohol, Tobacco, and Prescription Drugs: The Relationship With Illicit Drugs in the Treatment of Substance Users. Substance Use and Misuse, 2012, 47, 963-971.	1.4	15
374	A Comparison of Attitudes Toward Cognitive Enhancement and Legalized Doping in Sport in a Community Sample of Australian Adults. American Journal of Bioethics Primary Research, 2012, 3, 81-86.	1.5	24
375	Stimulant use disorders: Characteristics and comorbidity in an Australian population sample. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1173-1181.	2.3	27
376	Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Australian and New Zealand Journal of Psychiatry, 2012, 46, 958-965.	2.3	22
377	Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1182-1192.	2.3	60
378	A longitudinal study of the bi-directional relationship between tobacco smoking and psychological distress in a community sample of young Australian women. Psychological Medicine, 2012, 42, 1273-1282.	4.5	43

#	ARTICLE	IF	CITATIONS
379	The neurobiology of overeating. EMBO Reports, 2012, 13, 785-790.	4.5	22
380	Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet, The, 2012, 379, 55-70.	13.7	1,074
381	Analysis of national data shows mixed evidence of hardening among Australian smokers. Australian and New Zealand Journal of Public Health, 2012, 36, 408-414.	1.8	20
382	Addiction May Not Be a Compulsive Brain Disease, But It Is More Than Purposeful Medication of Untreated Psychiatric Disorders. AJOB Neuroscience, 2012, 3, 54-55.	1.1	3
383	Commentary on <sc>K</sc>elty & <sc>H</sc>ulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. Addiction, 2012, 107, 1825-1826.	3.3	2
384	Research methods and statistical techniques in addiction. Addiction, 2012, 107, 1724-1725.	3.3	0
385	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
386	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
387	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
388	Lessons for Enhancement From the History of Cocaine and Amphetamine Use. AJOB Neuroscience, 2012, 3, 24-29.	1.1	30
389	Letter to the Editor: Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase, 2012, 18, 181-184.	0.6	18
390	A longitudinal evaluation of a project-based learning initiative in an engineering undergraduate programme. European Journal of Engineering Education, 2012, 37, 155-165.	2.3	29
391	Response to commentaries: Slowing down the rush to translation in personal genomics. Addiction, 2012, 107, 2081-2081.	3.3	0
392	Avoiding Selective Ethical Objections to Nudges. American Journal of Bioethics, 2012, 12, 12-14.	0.9	6
393	Identifying Trustworthy Experts: How Do Policymakers Find and Assess Public Health Researchers Worth Consulting or Collaborating With?. PLoS ONE, 2012, 7, e32665.	2.5	58
394	How should we regulate smokeless tobacco products and eâ€“cigarettes?. Medical Journal of Australia, 2012, 197, 611-612.	1.7	12
395	Griffith Edwards. BMJ, The, 2012, 345, e7234-e7234.	6.0	0
396	Psychosis in Indigenous populations of Cape York and the Torres Strait. Medical Journal of Australia, 2012, 196, 133-135.	1.7	33

#	ARTICLE	IF	CITATIONS
397	Is the non-medical use of prescription stimulants a problem in Australia?. Medical Journal of Australia, 2012, 197, 145-145.	1.7	1
398	Driving while under the influence of cannabis. BMJ: British Medical Journal, 2012, 344, e595-e595.	2.3	7
399	What place, if any, does information on putative cardioprotective effects of moderate alcohol use have in safer drinking guidelines?. Drug and Alcohol Review, 2012, 31, 194-197.	2.1	11
400	Compulsive use of dopamine replacement therapy: a model for stimulant drug addiction?. Addiction, 2012, 107, 241-247.	3.3	26
401	Under what conditions is it ethical to offer incentives to encourage drug-using women to use long-acting forms of contraception?. Addiction, 2012, 107, 1036-1041.	3.3	32
402	STIMULATING DEBATE IN THE FIELD OF ADDICTION. Addiction, 2012, 107, 253-253.	3.3	2
403	Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents?. Addiction, 2012, 107, 801-809.	3.3	9
404	Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. Addiction, 2012, 107, 2069-2074.	3.3	23
405	IS DEEP BRAIN STIMULATION FOR ADDICTION AN ACCEPTABLE CRIME CONTROL MEASURE?. Addiction, 2012, 107, 1360-1360.	3.3	5
406	An analysis of ethical issues in using wastewater analysis to monitor illicit drug use. Addiction, 2012, 107, 1767-1773.	3.3	78
407	Compulsory detention, forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction. Addiction, 2012, 107, 1891-1893.	3.3	34
408	EXPLORING CONDITIONS UNDER WHICH IT MAY BE ETHICAL TO OFFER INCENTIVES TO ENCOURAGE DRUG-USEING WOMEN TO USE LONG-ACTING FORMS OF CONTRACEPTION. Addiction, 2012, 107, 1049-1050.	3.3	5
409	The perceived health risks of cannabis use in an Australian household survey. Drug and Alcohol Review, 2012, 31, 809-812.	2.1	7
410	Emerging Neurobiological Treatments of Addiction. , 2012, , 95-113.		3
411	The evolution of population policy in Viet Nam. Asia-Pacific Population Journal, 2012, 27, 41-56.	0.5	5
412	Population Approaches to Alcohol, Tobacco and Drugs. , 2012, , 247-260.		1
413	Introduction: What is Addiction Neuroethics and Why Does it Matter?. , 2012, , xvii-xxv.		2
414	Technical, Ethical and Social Issues in the Bioprediction of Addiction Liability and Treatment Response. , 2012, , 115-135.		0

#	ARTICLE	IF	CITATIONS
415	An evaluation of a project-based learning initiative in engineering education. <i>European Journal of Engineering Education</i> , 2011, 36, 357-365.	2.3	83
416	Mortality among cocaine users: A systematic review of cohort studies. <i>Drug and Alcohol Dependence</i> , 2011, 113, 88-95.	3.2	182
417	What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. <i>Drug and Alcohol Dependence</i> , 2011, 117, 85-101.	3.2	114
418	Refining the estimation of illicit drug consumptions from wastewater analysis: Co-analysis of prescription pharmaceuticals and uncertainty assessment. <i>Water Research</i> , 2011, 45, 4437-4448.	11.3	196
419	Grand challenges in global mental health. <i>Nature</i> , 2011, 475, 27-30.	27.8	1,654
420	The Australian alcopops tax revisited. <i>Lancet, The</i> , 2011, 377, 1136-1137.	13.7	15
421	Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A Narrative Review of Evidence and Recommendations. <i>Canadian Journal of Public Health</i> , 2011, 102, 324-327.	2.3	72
422	Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia. <i>Medical Journal of Australia</i> , 2011, 195, 248-249.	1.7	21
423	Democratising assessment of researchers'™ track records: a simple proposal. <i>Medical Journal of Australia</i> , 2011, 195, 147-148.	1.7	1
424	Depression and psychological distress in tobacco smokers and people with cannabis dependence in the National Survey of Mental Health and Wellbeing. <i>Medical Journal of Australia</i> , 2011, 195, S12-5.	1.7	22
425	What are the major drivers of prevalent disability burden in young Australians?. <i>Medical Journal of Australia</i> , 2011, 194, 232-235.	1.7	47
426	Smart Drugs 'As Common As Coffee' Media Hype about Neuroenhancement. <i>PLoS ONE</i> , 2011, 6, e28416.	2.5	149
427	Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. <i>Current Opinion in Psychiatry</i> , 2011, 24, 191-196.	6.3	24
428	Drug trafficking: Time to abolish the death penalty. <i>Journal of Substance Use</i> , 2011, 16, 259-262.	0.7	2
429	The association between cannabis use and depression: a review of the evidence. , 2011, , 114-128.		4
430	Galvanizers, Guides, Champions, and Shields: The Many Ways That Policymakers Use Public Health Researchers. <i>Milbank Quarterly</i> , 2011, 89, 564-598.	4.4	48
431	Cigarette tax and public health: what are the implications of financially stressed smokers for the effects of price increases on smoking prevalence?. <i>Addiction</i> , 2011, 106, 622-630.	3.3	30
432	Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. <i>Addiction</i> , 2011, 106, 283-293.	3.3	79

#	ARTICLE	IF	CITATIONS
433	Proposals to trial deep brain stimulation to treat addiction are premature. <i>Addiction</i> , 2011, 106, 235-237.	3.3	40
434	<i>Addiction's</i> priorities when evaluating submissions. <i>Addiction</i> , 2011, 106, 463-465.	3.3	1
435	UNTESTED ASSUMPTIONS ABOUT PUTATIVE NEUROENHANCEMENT. <i>Addiction</i> , 2011, 106, 1190-1191.	3.3	1
436	MAKING SPACE FOR CANNABIS POLICY EXPERIMENTS. <i>Addiction</i> , 2011, 106, 1192-1193.	3.3	2
437	SCIENCE, SAFETY AND COSTS MAKE DEEP BRAIN STIMULATION FOR ADDICTION A LOW PRIORITY: A REPLY TO VORSPAN <i>et al.</i> (2011) AND KUHN <i>et al.</i> (2011). <i>Addiction</i> , 2011, 106, 1537-1538.	3.3	4
438	BEWARE OF ALLOWING THE IDEAL TO BE THE ENEMY OF THE GOOD. <i>Addiction</i> , 2011, 106, 1555-1556.	3.3	3
439	Academic doping or Viagra for the brain?. <i>EMBO Reports</i> , 2011, 12, 197-201.	4.5	34
440	Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 220-225.	1.8	51
441	From 'our world' to the 'real world': Exploring the views and behaviour of policy-influential Australian public health researchers. <i>Social Science and Medicine</i> , 2011, 72, 1047-1055.	3.8	67
442	Public attitudes towards human life extension by intervening in ageing. <i>Journal of Aging Studies</i> , 2011, 25, 73-83.	1.4	17
443	Deflating the Neuroenhancement Bubble. <i>AJOB Neuroscience</i> , 2011, 2, 38-43.	1.1	62
444	Drug-Induced Impulse Control Disorders: A Prospectus for Neuroethical Analysis. <i>Neuroethics</i> , 2011, 4, 91-102.	2.8	19
445	Ethical Issues Raised by Proposals to Treat Addiction Using Deep Brain Stimulation. <i>Neuroethics</i> , 2011, 4, 129-142.	2.8	33
446	Indirect evidence of the contribution of prenatal sex selection practices to the high sex ratio at birth in Vietnam. <i>Journal of Population Research</i> , 2011, 28, 293-299.	1.1	4
447	Utilization of anti-Parkinson drugs in Australia: 1995-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 450-456.	1.9	16
448	Cannabis and the increased incidence and persistence of psychosis. <i>BMJ: British Medical Journal</i> , 2011, 342, d719-d719.	2.3	19
449	Psychological Distress is Associated with Tobacco Smoking and Quitting Behaviour in the Australian Population: Evidence from National Cross-Sectional Surveys. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 170-178.	2.3	40
450	Psychiatric Drug Prescribing in Elderly Australians: Time for Action. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 705-708.	2.3	11

#	ARTICLE	IF	CITATIONS
451	Deep Brain Stimulation in Parkinsonian Patientsâ€™ Implications for Trialing DBS in Intractable Psychiatric Disorders. <i>AJOB Neuroscience</i> , 2011, 2, 14-15.	1.1	5
452	In the Face of Uncertainty About the Risks of Low-Level Drinking, Abstinence Is Prudent, Not Misogynistic, Advice. <i>American Journal of Bioethics</i> , 2011, 11, 66-67.	0.9	2
453	Begging Important Questions About Cognitive Enhancement, Again. <i>American Journal of Bioethics</i> , 2011, 11, 14-15.	0.9	5
454	The Association between Four Citation Metrics and Peer Rankings of Research Influence of Australian Researchers in Six Fields of Public Health. <i>PLoS ONE</i> , 2011, 6, e18521.	2.5	35
455	Is deep brain stimulation a prospective "cure" for addiction?. <i>F1000 Medicine Reports</i> , 2011, 3, 4.	2.9	14
456	Alcohol tax reform: now is the time. <i>Medical Journal of Australia</i> , 2011, 195, 660-660.	1.7	2
457	Drug Trafficking: Time to Abolish the Death Penalty. <i>International Journal of Mental Health and Addiction</i> , 2010, 8, 616-619.	7.4	0
458	A cautionary bibliometric tale of two cities. <i>Scientometrics</i> , 2010, 84, 317-320.	3.0	7
459	Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. <i>International Journal of Drug Policy</i> , 2010, 21, 10-19.	3.3	59
460	Harm reduction policies for tobacco users. <i>International Journal of Drug Policy</i> , 2010, 21, 129-130.	3.3	21
461	THE NEED FOR MORE EXPLANATORY HUMILITY IN ADDICTION NEUROBIOLOGY. <i>Addiction</i> , 2010, 105, 790-791.	3.3	9
462	Testing for cannabis in the workplace: a review of the evidence. <i>Addiction</i> , 2010, 105, 408-416.	3.3	47
463	The epidemiology of cannabis use and cannabisâ€™related harm in Australia 1993â€™2007. <i>Addiction</i> , 2010, 105, 1071-1079.	3.3	42
464	WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS?. <i>Addiction</i> , 2010, 105, 1332-1333.	3.3	5
465	What are the policy lessons of National Alcohol Prohibition in the United States, 1920â€™1933?. <i>Addiction</i> , 2010, 105, 1164-1173.	3.3	106
466	A renewed call for action on alcohol policy. <i>Addiction</i> , 2010, 105, 767-768.	3.3	3
467	What would evidence-informed drug policies look like?. <i>Addiction</i> , 2010, 105, 1135-1136.	3.3	2
468	Prevalence and correlates of DSMâ€™IV alcohol abuse and dependence in Australia: findings of the 2007 National Survey of Mental Health and Wellbeing. <i>Addiction</i> , 2010, 105, 2085-2094.	3.3	203

#	ARTICLE	IF	CITATIONS
469	The enhancement use of neuropharmaceuticals: more scepticism and caution needed. <i>Addiction</i> , 2010, 105, 2041-2043.	3.3	56
470	Listening to public concerns about human life extension. <i>EMBO Reports</i> , 2010, 11, 735-737.	4.5	3
471	Anticipating the use of life extension technologies. <i>EMBO Reports</i> , 2010, 11, 334-338.	4.5	8
472	The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia 2000 to 2006. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 315-319.	1.8	4
473	Epidemiology of alcohol-related burden of disease among Indigenous Australians. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, S47-S51.	1.8	49
474	Forecasting future tobacco control policy: where to next?. <i>Australian and New Zealand Journal of Public Health</i> , 2010, 34, 447-450.	1.8	12
475	Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. <i>Drug and Alcohol Review</i> , 2010, 29, 318-330.	2.1	141
476	Smokeless tobacco products: Unrecognised regulatory and policy opportunities. <i>Drug and Alcohol Review</i> , 2010, 29, 119-120.	2.1	0
477	Why we need tobacco sales data for good tobacco control. <i>Medical Journal of Australia</i> , 2010, 192, 3-4.	1.7	14
478	Alcohol policy reform in Australia: what can we learn from the evidence?. <i>Medical Journal of Australia</i> , 2010, 192, 468-470.	1.7	33
479	How can we reduce alcohol-related road crash deaths among young Australians?. <i>Medical Journal of Australia</i> , 2010, 192, 464-466.	1.7	7
480	Per capita alcohol consumption in Australia: will the real trend please step forward?. <i>Medical Journal of Australia</i> , 2010, 193, 594-597.	1.7	40
481	Begging the Question: Presupposing That TMS Can Be Shown to Enhance Eyewitness Testimony. <i>AJOB Neuroscience</i> , 2010, 1, 34-35.	1.1	2
482	Weak evidence for large claims contribute to the phantom debate. <i>BioSocieties</i> , 2010, 5, 482-483.	1.3	22
483	ASSESSING THE QUALITY OF DATA FOR ANALYSING THE SEX RATIO AT BIRTH IN VIET NAM. <i>Asian Population Studies</i> , 2010, 6, 263-287.	1.5	10
484	Is There Evidence of "Hardening" Among Australian Smokers Between 1997 and 2007? Analyses of the Australian National Surveys of Mental Health and Well-Being. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 1132-1136.	2.3	27
485	Patterns of Antipsychotic Medication Use in Australia 2002-2007. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 372-377.	2.3	83
486	Does a lack of specificity rule out a causal relationship between cannabis use and schizophrenia?. <i>Addiction Research and Theory</i> , 2010, 18, 606-608.	1.9	1

#	ARTICLE	IF	CITATIONS
487	Being More Realistic about the Public Health Impact of Genomic Medicine. PLoS Medicine, 2010, 7, e1000347.	8.4	44
488	Beyond the Right to Injectable Heroin. AJOB Neuroscience, 2010, 1, 48-49.	1.1	1
489	Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ: British Medical Journal, 2010, 341, c4851-c4851.	2.3	114
490	Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. Addictive Behaviors, 2010, 35, 741-749.	3.0	106
491	Adverse health effects of non-medical cannabis use " Authors' reply. Lancet, The, 2010, 375, 197.	13.7	0
492	Ending inequities in access to effective pain relief?. Lancet, The, 2010, 376, 856-857.	13.7	11
493	The "calcopops" tax: heading in the right direction. Medical Journal of Australia, 2009, 190, 294-295.	1.7	42
494	Sociodemographic correlates of antidepressant utilisation in Australia. Medical Journal of Australia, 2009, 190, 479-483.	1.7	33
495	Cannabis Use in Canada: The Need for a "Public Health"™ Approach. Canadian Journal of Public Health, 2009, 100, 101-103.	2.3	48
496	Drug Trafficking: Time to Abolish the Death Penalty. Journal of Groups in Addiction and Recovery, 2009, 4, 322-326.	0.4	0
497	Predicting the future prevalence of cigarette smoking in Australia: how low can we go and by when?. Tobacco Control, 2009, 18, 183-189.	3.2	59
498	The Australian Illicit Drug Reporting System: Monitoring Trends in Illicit Drug Availability, Use and Drug-Related Harm in Australia 1996"2006. Contemporary Drug Problems, 2009, 36, 643-661.	1.6	9
499	Clashes between the government and its expert advisers. BMJ: British Medical Journal, 2009, 339, b4662-b4662.	2.3	1
500	Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?. PLoS Medicine, 2009, 6, e1000133.	8.4	41
501	Scare-Mongering and the Anticipatory Ethics of Experimental Technologies. American Journal of Bioethics, 2009, 9, 47-48.	0.9	21
502	Direct-to-Consumer Genome-Wide Scans: Astrologicogenomics or Simple Scams?. American Journal of Bioethics, 2009, 9, 54-56.	0.9	10
503	Mapping Community Concerns About Radical Extensions of Human Life Expectancy. American Journal of Bioethics, 2009, 9, W4-W5.	0.9	1
504	Systematic Review of Interventions to Improve Prescribing. Annals of Pharmacotherapy, 2009, 43, 502-513.	1.9	121

#	ARTICLE	IF	CITATIONS
505	State of the Nation's Mental Health 2007. Australian and New Zealand Journal of Psychiatry, 2009, 43, 591-593.	2.3	6
506	Ethical Concerns in the Community About Technologies to Extend Human Life Span. American Journal of Bioethics, 2009, 9, 68-76.	0.9	35
507	Community perceptions on the significant extension of life: An exploratory study among urban adults in Brisbane, Australia. Social Science and Medicine, 2009, 68, 496-503.	3.8	24
508	The adverse health effects of cannabis use: What are they, and what are their implications for policy?. International Journal of Drug Policy, 2009, 20, 458-466.	3.3	160
509	Professional and personal attitudes of researchers in ageing towards life extension. Biogerontology, 2009, 10, 73-81.	3.9	8
510	A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety, 2009, 18, 93-103.	1.9	87
511	Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction, 2009, 104, 118-126.	3.3	27
512	Drug trafficking: time to abolish the death penalty. Addiction, 2009, 104, 1267-1269.	3.3	9
513	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction, 2009, 104, 1363-1372.	3.3	81
514	[Commentary] THE POTENTIAL ROLE OF SNUS IN TOBACCO HARM REDUCTION. Addiction, 2009, 104, 1586-1587.	3.3	16
515	Estimating the burden of disease attributable to illicit drug use and mental disorders: what is the Global Burden of Disease 2005 and why does it matter?. Addiction, 2009, 104, 1466-1471.	3.3	20
516	Anticipating the anti-ageing pill. EMBO Reports, 2009, 10, 108-113.	4.5	8
517	Challenges in reducing cannabis-related harm in Australia. Drug and Alcohol Review, 2009, 28, 110-116.	2.1	4
518	Smokeless tobacco use in Australia. Drug and Alcohol Review, 2009, 28, 284-291.	2.1	6
519	Mental Disorders and Socioeconomic Status: Impact on Population Risk of Attempted Suicide in Australia. Suicide and Life-Threatening Behavior, 2009, 39, 471-481.	1.9	14
520	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence, 2009, 105, 9-15.	3.2	309
521	Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence, 2009, 105, 1-8.	3.2	93
522	Supping with the Devil? The role of law in promoting tobacco harm reduction using low nitrosamine smokeless tobacco products. Public Health, 2009, 123, 287-291.	2.9	21

#	ARTICLE	IF	CITATIONS
523	Alcohol industry and government revenue derived from underage drinking by Australian adolescents 2005. Addictive Behaviors, 2009, 34, 75-81.	3.0	9
524	Reprint of "Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base" Addictive Behaviors, 2009, 34, 795-799.	3.0	15
525	Ethical, Social, and Personal Implications of Extended Human Lifespan Identified by Members of the Public. Rejuvenation Research, 2009, 12, 351-357.	1.8	22
526	Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. Addictive Behaviors, 2009, 34, 526-530.	3.0	53
527	Adverse health effects of non-medical cannabis use. Lancet, The, 2009, 374, 1383-1391.	13.7	941
528	The challenges in developing a rational cannabis policy. Current Opinion in Psychiatry, 2009, 22, 258-262.	6.3	33
529	Policy forum. Drugs and Alcohol Today, 2009, 9, 11-14.	0.7	0
530	Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug and Alcohol Review, 2008, 27, 1-3.	2.1	18
531	The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. Drug and Alcohol Review, 2008, 27, 145-151.	2.1	36
532	Australian smokers' use of bupropion and nicotine replacement therapies and their relation to reimbursement, Australia 2001-05. Drug and Alcohol Review, 2008, 27, 160-164.	2.1	6
533	The genetics of nicotine addiction liability: ethical and social policy implications. Addiction, 2008, 103, 350-359.	3.3	34
534	Explaining the convergence of male and female smoking prevalence in Australia. Addiction, 2008, 103, 487-495.	3.3	7
535	Thinking about the unthinkable: a <i>de facto</i> prohibition on smoked tobacco products. Addiction, 2008, 103, 873-874.	3.3	28
536	Marketing Health: Smoking and the Discourse of Public Health in Britain, 1945-2000. Addiction, 2008, 103, 515-516.	3.3	0
537	The contribution of research to the development of a national cannabis policy in Australia. Addiction, 2008, 103, 712-720.	3.3	17
538	[Commentary] ADOLESCENT CANNABIS USE AND ADULT LIFE CHANCES. Addiction, 2008, 103, 977-978.	3.3	36
539	The use of depot naltrexone under legal coercion: the case for caution. Addiction, 2008, 103, 1922-1924.	3.3	17
540	Informed consent to opioid agonist maintenance treatment: Recommended ethical guidelines. International Journal of Drug Policy, 2008, 19, 79-89.	3.3	29

#	ARTICLE	IF	CITATIONS
541	Australian heroin seizures and the causes of the 2001 heroin shortage. International Journal of Drug Policy, 2008, 19, 293-294.	3.3	1
542	CANNABIS ABUSE AND DEPENDENCE. , 2008, , 117-148.		4
543	Oral substitution treatments for opioid dependence. Lancet, The, 2008, 371, 2150-2151.	13.7	13
544	Analysis of socio-political and health practices influencing sex ratio at birth in Viet Nam. Reproductive Health Matters, 2008, 16, 176-184.	1.2	31
545	How Will Information About the Genetic Risk of Mental Disorders Impact on Stigma?. Australian and New Zealand Journal of Psychiatry, 2008, 42, 214-220.	2.3	21
546	The Implications of Genetic Susceptibility for the Prevention of Colorectal Cancer: A Qualitative Study of Older Adults’ Understanding. Public Health Genomics, 2008, 11, 283-288.	1.0	9
547	The adverse effects of cannabinoids: implications for use of medical marijuana. Cmaj, 2008, 178, 1685-1686.	2.0	28
548	Five Genetic Variants Associated with Prostate Cancer. New England Journal of Medicine, 2008, 358, 2738-2741.	27.0	5
549	The Issue of Consent in Research that Administers Drugs of Addiction to Addicted Persons. Accountability in Research, 2008, 15, 209-225.	2.4	23
550	Cannabis use and the risk of developing a psychotic disorder. World Psychiatry, 2008, 7, 68-71.	10.4	109
551	Response to Brewer. Drug and Alcohol Review, 2008, 27, 448-449.	2.1	0
552	Should Australia lift its ban on low nitrosamine smokeless tobacco products?. Medical Journal of Australia, 2008, 188, 44-46.	1.7	13
553	Obstacles to a Regulated Cannabis Market. Canadian Journal of Psychiatry, 2008, 53, 798-798.	1.9	1
554	Should We Recriminalize Cannabis Use? The Case against. Canadian Journal of Psychiatry, 2008, 53, 793-794.	1.9	3
555	Alcohol sales data are essential for good public policies towards alcohol. Medical Journal of Australia, 2008, 189, 188-189.	1.7	13
556	The Social Implications of Neurobiological Explanations of Resistible Compulsions. American Journal of Bioethics, 2007, 7, 15-17.	0.9	12
557	Debunking Alarmist Objections to the Pharmacological Prevention of PTSD. American Journal of Bioethics, 2007, 7, 23-25.	0.9	10
558	Persons and Personification. American Journal of Bioethics, 2007, 7, 57-58.	0.9	2

#	ARTICLE	IF	CITATIONS
559	A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tobacco Control, 2007, 16, 53-58.	3.2	18
560	Why Do They Do It?. Public Health Genomics, 2007, 10, 61-71.	1.0	24
561	Costâ€effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 119-128.	1.4	7
562	Substance use and the adolescent brain: A toxic combination?. Journal of Psychopharmacology, 2007, 21, 792-794.	4.0	116
563	Assessing the impact of prescribed medicines on health outcomes. Australia and New Zealand Health Policy, 2007, 4, 1.	2.2	8
564	Cannabis-Induced Psychosis among Aboriginal People in the Northwest Territories. Canadian Journal of Psychiatry, 2007, 52, 475-476.	1.9	0
565	Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion in Psychiatry, 2007, 20, 393-397.	6.3	139
566	The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological Medicine, 2007, 37, 927-934.	4.5	79
567	Psychoactive drugs of misuse: rationalising the irrational. Lancet, The, 2007, 369, 972.	13.7	8
568	Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet, The, 2007, 369, 2010-2014.	13.7	135
569	Clinical update: codeine maintenance in opioid dependence. Lancet, The, 2007, 370, 550-552.	13.7	10
570	Swedish snus for tobacco harm reduction â€ Authors' reply. Lancet, The, 2007, 370, 1206-1207.	13.7	6
571	UK classification of cannabis: is a change needed and why?. Lancet, The, 2007, 370, 1541.	13.7	3
572	Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia, 2007, 186, 152-153.	1.7	41
573	The search for Methuselah. EMBO Reports, 2007, 8, 888-891.	4.5	17
574	Statins down under. British Journal of Clinical Pharmacology, 2007, 63, 125-127.	2.4	11
575	Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction, 2007, 102, 607-615.	3.3	152
576	Biomedicalization of Alcohol Studies: Ideological Shifts and Institutional Challenges. Addiction, 2007, 102, 494-495.	3.3	0

#	ARTICLE	IF	CITATIONS
577	WHAT'S IN A NAME?. Addiction, 2007, 102, 692-692.	3.3	33
578	Standardizing terminology in addiction science: to achieve the impossible dream. Addiction, 2007, 102, 1015-1018.	3.3	11
579	Drugs and the Future: Brain Science, Addiction and Society. Addiction, 2007, 102, 1170-1170.	3.3	0
580	Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: an overdue topic for research. Addiction, 2007, 102, 1685-1688.	3.3	16
581	[Commentary] REDUCING CANNABIS-IMPAIRED DRIVING: IS THERE SUFFICIENT EVIDENCE FOR DRUG TESTING OF DRIVERS?. Addiction, 2007, 102, 1918-1919.	3.3	12
582	Community Attitudes to the Regulation of Life Extension. Annals of the New York Academy of Sciences, 2007, 1114, 288-299.	3.8	5
583	Should the Health Community Promote Smokeless Tobacco (Snus) as a Harm Reduction Measure?. PLoS Medicine, 2007, 4, e185.	8.4	90
584	Ethical and policy issues in the translation of genetic and neuroscience research on addiction. , 2007, , 439-457.		1
585	Is cannabis use psychotogenic?. Lancet, The, 2006, 367, 193-195.	13.7	44
586	How have the SSRI antidepressants affected suicide risk?. Lancet, The, 2006, 367, 1959-1962.	13.7	53
587	What are the Policy Implications of the Evidence on Cannabis and Psychosis?. Canadian Journal of Psychiatry, 2006, 51, 566-574.	1.9	41
588	Assessing the wisdom of funding DrinkWise. Medical Journal of Australia, 2006, 185, 635-636.	1.7	17
589	Is Cannabis Use a Contributory Cause of Psychosis?. Canadian Journal of Psychiatry, 2006, 51, 556-565.	1.9	105
590	The Ethics of Paying Drug Users Who Participate in Research: A Review and Practical Recommendations. Journal of Empirical Research on Human Research Ethics, 2006, 1, 21-35.	1.3	58
591	The AUDIT questionnaire: choosing a cut-off score. Addiction, 2006, 90, 1349-1356.	3.3	200
592	Management and treatment efficacy of drug and alcohol problems: what do doctors believe?. Addiction, 2006, 90, 1357-1366.	3.3	22
593	The "lessons" of the Australian "heroin shortage". Substance Abuse Treatment, Prevention, and Policy, 2006, 1, 11.	2.2	47
594	“Occasional” and “social” smokers: potential target groups for smoking cessation campaigns?. Australian and New Zealand Journal of Public Health, 2006, 30, 550-554.	1.8	23

#	ARTICLE	IF	CITATIONS
595	Strong and weak lifespan extension: what is most feasible and likely?. Australasian Journal on Ageing, 2006, 25, 58-62.	0.9	13
596	What does the community think about lifespan extension technologies? The need for an empirical base for ethical and policy debates. Australasian Journal on Ageing, 2006, 25, 180-184.	0.9	12
597	The evidence base for registration and reimbursement of new pharmaceuticals in cancer treatment: Surrogate and real health outcomes. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 119-121.	1.1	0
598	Stereotactic neurosurgical treatment of addiction: minimizing the chances of another "great and desperate cure". Addiction, 2006, 101, 1-3.	3.3	38
599	ETHICAL EYE: DRUG ADDICTION. Addiction, 2006, 101, 460-461.	3.3	0
600	DISSECTING THE CAUSAL ANATOMY OF THE LINK BETWEEN CANNABIS AND OTHER ILLICIT DRUGS. Addiction, 2006, 101, 472-473.	3.3	12
601	Ensuring that addiction science is deserving of public trust. Addiction, 2006, 101, 1223-1224.	3.3	9
602	Avoiding potential misuses of addiction brain science. Addiction, 2006, 101, 1529-1532.	3.3	11
603	CANADIAN HEROIN SUPPLY AND THE AUSTRALIAN "HEROIN SHORTAGE". Addiction, 2006, 101, 1667-1668.	3.3	1
604	Delivering on the promise of human stem cell research. What are the real barriers?. EMBO Reports, 2006, 7, 1188-1192.	4.5	12
605	Documenting the heroin shortage in New South Wales. Drug and Alcohol Review, 2006, 25, 297-305.	2.1	21
606	Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review, 2006, 25, 307-313.	2.1	30
607	Minimising research censorship by government funders. International Journal of Drug Policy, 2006, 17, 240-241.	3.3	7
608	Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical Research Methodology, 2006, 6, 16.	3.1	67
609	How have the Selective Serotonin Reuptake Inhibitor Antidepressants Affected Suicide Mortality?. Australian and New Zealand Journal of Psychiatry, 2006, 40, 941-950.	2.3	43
610	The Mental Health Risks of Adolescent Cannabis Use. PLoS Medicine, 2006, 3, e39.	8.4	38
611	The regulatory challenges in engineering a safer tipple. Journal of Psychopharmacology, 2006, 20, 321-322.	4.0	1
612	Cannabis use and the Mental Health of Young People. Australian and New Zealand Journal of Psychiatry, 2006, 40, 105-113.	2.3	83

#	ARTICLE	IF	CITATIONS
613	Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sexually Transmitted Infections, 2006, 82, iii56-iii63.	1.9	81
614	Cannabis use and the mental health of young people. Australian and New Zealand Journal of Psychiatry, 2006, 40, 105-113.	2.3	10
615	A Cautious Case for Cannabis Depenalization. , 2006, , 91-112.		0
616	How common is comorbidity and why does it occur?. Australian Psychologist, 2005, 40, 81-87.	1.6	9
617	Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug and Alcohol Review, 2005, 24, 39-48.	2.1	217
618	Evaluating explanations of the Australian "heroin shortage". Addiction, 2005, 100, 459-469.	3.3	105
619	Effects of a sustained heroin shortage in three Australian States. Addiction, 2005, 100, 908-920.	3.3	121
620	The integrity of the science base: a test case. Addiction, 2005, 100, 581-584.	3.3	20
621	MAPPING THE CONSEQUENCES OF AN UNANTICIPATED DRUG SUPPLY CHANGE OF UNCERTAIN ORIGINS: RESPONSE TO THE COMMENTARIES. Addiction, 2005, 100, 930-932.	3.3	3
622	Who wants to live forever?. EMBO Reports, 2005, 6, 98-102.	4.5	25
623	The prospects for tobacco harm reduction. International Journal of Drug Policy, 2005, 16, 139-142.	3.3	5
624	Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy, 2005, 16, 300-307.	3.3	11
625	Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime?. BMC Public Health, 2005, 5, 40.	2.9	21
626	The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia, 2005, 182, 20-23.	1.7	45
627	Will Nicotine Genetics and a Nicotine Vaccine Prevent Cigarette Smoking and Smoking-Related Diseases?. PLoS Medicine, 2005, 2, e266.	8.4	26
628	Ethical Considerations for Drug Abuse Epidemiologic Research. , 2005, , 145-157.		0
629	British drinking: a suitable case for treatment?. BMJ: British Medical Journal, 2005, 331, 527-528.	2.3	25
630	Being realistic about benefits of supervised injecting facilities. Lancet, The, 2005, 366, 271-272.	13.7	14

#	ARTICLE	IF	CITATIONS
631	The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence, 2005, 79, 129-135.	3.2	29
632	Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. Drug and Alcohol Dependence, 2005, 79, 397-404.	3.2	13
633	The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health, 2005, 5, 84.	2.9	8
634	Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncology, The, 2005, 6, 35-42.	10.7	74
635	The association between cannabis use and depression: a review of the evidence. , 2004, , 54-74.		0
636	Is there a specific "cannabis psychosis"? , 2004, , 89-100.		15
637	Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. Journal of Medical Ethics, 2004, 30, 337-340.	1.8	25
638	Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ: British Medical Journal, 2004, 329, 428-429.	2.3	33
639	The policy and ethical implications of genetic research on attention deficit hyperactivity disorder. Australian and New Zealand Journal of Psychiatry, 2004, 38, 10-19.	2.3	8
640	Genetic screening for susceptibility to depression: can we and should we?. Australian and New Zealand Journal of Psychiatry, 2004, 38, 73-80.	2.3	7
641	RETROSPECTIONS OF A RECOVERING DRUG RESEARCHER. Addiction, 2004, 99, 153-154.	3.3	1
642	The psychotogenic effects of cannabis use: challenges in reducing residual uncertainties and communicating the risks. Addiction, 2004, 99, 511-512.	3.3	5
643	The contribution of research to Australian policy responses to heroin dependence 1990-2001: a personal retrospection. Addiction, 2004, 99, 560-569.	3.3	20
644	Reply to Wodak. Addiction, 2004, 99, 1064-1064.	3.3	1
645	An invitation to an alcohol industry lobby to help decide public funding of alcohol research and professional training: a decision that should be reversed. Addiction, 2004, 99, 1235-1236.	3.3	19
646	New Treatments for Addiction: Behavioural, Ethical, Legal and Social Questions. Addiction, 2004, 99, 1481-1481.	3.3	1
647	The prediction of disease risk in genomic medicine. EMBO Reports, 2004, 5, S22-6.	4.5	22
648	Feeling "better than well". EMBO Reports, 2004, 5, 1105-1109.	4.5	49

#	ARTICLE	IF	CITATIONS
649	Cannabis use and psychotic disorders: an update. Drug and Alcohol Review, 2004, 23, 433-443.	2.1	88
650	Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations. Journal of Molecular Medicine, 2004, 82, 21-30.	3.9	25
651	Neuroscience research on the addictions: A prospectus for future ethical and policy analysis. Addictive Behaviors, 2004, 29, 1481-1495.	3.0	37
652	The Policy and Ethical Implications of Genetic Research on Attention Deficit Hyperactivity Disorder. Australian and New Zealand Journal of Psychiatry, 2004, 38, 10-19.	2.3	1
653	Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug and Alcohol Review, 2003, 22, 7-13.	2.1	61
654	Heroin Overdose: Research and Evidence-Based Intervention. Journal of Urban Health, 2003, 80, 189-200.	3.6	280
655	Decreased heroin availability in Sydney in early 2001. Addiction, 2003, 98, 93-95.	3.3	57
656	Addiction, neuroscience and ethics. Addiction, 2003, 98, 867-870.	3.3	23
657	Exploring the association between cannabis use and depression. Addiction, 2003, 98, 1493-1504.	3.3	470
658	Addiction, ethics and scientific freedom. Addiction, 2003, 98, 873-874.	3.3	4
659	Heroin addiction and the capacity for consent: a reply to charland. Addiction, 2003, 98, 1775-1776.	3.3	8
660	Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence, 2003, 71, 37-48.	3.2	242
661	A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence, 2003, 72, 59-65.	3.2	169
662	Medical Marijuana Initiatives. CNS Drugs, 2003, 17, 689-697.	5.9	33
663	Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ: British Medical Journal, 2003, 326, 1008-1008.	2.3	263
664	Antidepressant prescribing and suicide: Authors' reply. BMJ: British Medical Journal, 2003, 327, 289-289.	2.3	4
665	The Australian policy debate about human embryonic stem cell research. Health Law Review, 2003, 12, 27-33.	0.1	0
666	Heroin-assisted treatment as a response to the public health problem of opiate dependence. European Journal of Public Health, 2002, 12, 228-234.	0.3	82

#	ARTICLE	IF	CITATIONS
667	Property Crime and Income Generation by Heroin Users. Australian and New Zealand Journal of Criminology, 2002, 35, 187-202.	2.5	35
668	The genetics of tobacco use: methods, findings and policy implications. Tobacco Control, 2002, 11, 119-124.	3.2	93
669	Public policy and the prevention of substance-use disorders. Current Opinion in Psychiatry, 2002, 15, 235-239.	6.3	14
670	Harm Minimization in a Prohibition Context—Australia. Annals of the American Academy of Political and Social Science, 2002, 582, 80-93.	1.6	12
671	Cannabis use and mental health in young people: cohort study. BMJ: British Medical Journal, 2002, 325, 1195-1198.	2.3	809
672	The prospects for immunotherapy in smoking cessation. Lancet, The, 2002, 360, 1089-1091.	13.7	42
673	Breaking the deadlock over an Australian trial of injectable opioid maintenance. Medical Journal of Australia, 2002, 176, 72-73.	1.7	7
674	In reply: Separating politics and scientific research on heroin prescription. Medical Journal of Australia, 2002, 176, 450-450.	1.7	1
675	Cannabis and psychosis. Current Psychiatry Reports, 2002, 4, 191-196.	4.5	64
676	Another mirror shattered? Tobacco industry involvement suspected in a book which claims that nicotine is not addictive. Addiction, 2002, 97, 1-5.	3.3	8
677	Cannabis use and cancer. Addiction, 2002, 97, 243-247.	3.3	37
678	Heroin use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the Illicit Drug Reporting System (IDRS). Addiction, 2002, 97, 179-186.	3.3	60
679	Preventing drug misuse by young people: we need to do more than “just say no”. Addiction, 2002, 97, 478-481.	3.3	27
680	Getting the Cannabis Withdrawal Question into Proper Perspective: Comments on Smith. Addiction, 2002, 97, 754-754.	3.3	2
681	The long-term effectiveness of brief interventions for unsafe alcohol consumption: a 10-year follow-up. Addiction, 2002, 97, 665-675.	3.3	111
682	Hair morphine concentrations of fatal heroin overdose cases and living heroin users. Addiction, 2002, 97, 977-984.	3.3	54
683	Taking Darwin Seriously: More Than Telling Just So Stories. Addiction, 2002, 97, 472-473.	3.3	6
684	Educating government officials about the health risks of cannabis. Journal of Policy Analysis and Management, 2002, 21, 121.	1.4	1

#	ARTICLE	IF	CITATIONS
685	Property Crime and Income Generation by Heroin Users. Australian and New Zealand Journal of Criminology, 2002, 35, 187-202.	2.5	2
686	Gewohnheitsmäßiger Cannabiskonsum und Teilnahme am Straßenverkehr. , 2002, , 355-361.		0
687	Harm Minimization in a Prohibition Context—Australia. Annals of the American Academy of Political and Social Science, 2002, 582, 80-93.	1.6	3
688	Reducing the harms caused by cannabis use: the policy debate in Australia†. Drug and Alcohol Dependence, 2001, 62, 163-174.	3.2	43
689	Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Drug and Alcohol Dependence, 2001, 63, 147-153.	3.2	71
690	The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence, 2001, 64, 319-327.	3.2	140
691	Prevalence, comorbidity, disability and service utilisation. British Journal of Psychiatry, 2001, 178, 145-153.	2.8	847
692	The Policy Implications of Cannabis Dependence. , 2001, , 315-340.		4
693	The Adverse Health and Psychological Consequences of Cannabis Dependence. , 2001, , 106-128.		3
694	Allowing the medical use of cannabis. Medical Journal of Australia, 2001, 175, 39-40.	1.7	14
695	The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychological Medicine, 2001, 31, 659-668.	4.5	167
696	The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Social Psychiatry and Psychiatric Epidemiology, 2001, 36, 219-227.	3.1	120
697	No switching off the camera: howAddictionwill respond to infringements of ethical publishing expectation. Addiction, 2001, 96, 1391-1392.	3.3	1
698	Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction, 2001, 96, 1603-1614.	3.3	263
699	Back-projection estimates of the number of dependent heroin users in Australia. Addiction, 2001, 96, 433-443.	3.3	46
700	Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction, 2001, 96, 737-748.	3.3	109
701	Attention Deficit Hyperactivity Disorder and substance use disorders: is there a causal link?. Addiction, 2001, 96, 815-822.	3.3	101
702	Heroin overdose: causes and consequences. Addiction, 2001, 96, 1113-1125.	3.3	335

#	ARTICLE	IF	CITATIONS
703	Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. <i>Addiction</i> , 2001, 96, 1289-1296.	3.3	81
704	An overview of diversion strategies for Australian drug-related offenders. <i>Drug and Alcohol Review</i> , 2001, 20, 281-294.	2.1	33
705	Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders. <i>Drug and Alcohol Review</i> , 2001, 20, 369-383.	2.1	18
706	Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. <i>Australian and New Zealand Journal of Public Health</i> , 2001, 25, 447-450.	1.8	19
707	Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. <i>Drug and Alcohol Review</i> , 2001, 20, 193-199.	2.1	22
708	Challenges and Approaches to Estimating Mortality Attributable to the Use of Selected Illicit Drugs. <i>European Addiction Research</i> , 2001, 7, 104-116.	2.4	14
709	The effects of adolescent cannabis use on educational attainment: a review. <i>Addiction</i> , 2000, 95, 1621-1630.	3.3	459
710	Cannabis use and public health: assessing the burden. <i>Addiction</i> , 2000, 95, 485-490.	3.3	73
711	Cannabis Use and Psychosis: A Review of Clinical and Epidemiological Evidence. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 26-34.	2.3	160
712	Cohort trends in youth suicide in Australia 1964-1997. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 408-412.	2.3	3
713	The THC content of cannabis in Australia: evidence and implications. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 503-508.	1.8	48
714	Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 603-606.	1.8	26
715	Cohort trends in the age of initiation of drug use in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 421-426.	1.8	105
716	Longitudinal research: methods for maximizing subject follow-up. <i>Drug and Alcohol Review</i> , 2000, 19, 159-163.	2.1	9
717	The effects of the Cannabis Expiation Notice system on the prevalence of cannabis use in South Australia: evidence from the National Drug Strategy Household Surveys 1985-95. <i>Drug and Alcohol Review</i> , 2000, 19, 265-269.	2.1	43
718	How many dependent heroin users are there in Australia?. <i>Medical Journal of Australia</i> , 2000, 173, 528-531.	1.7	133
719	Cohort Trends in Youth Suicide in Australia 1964-1997. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 408-412.	2.3	21
720	Australia's Mental Health: An Overview of the General Population Survey. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 197-205.	2.3	317

#	ARTICLE	IF	CITATIONS
721	Alcohol- and Drug-Use Disorders in Australia: Implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2000, 34, 206-213.	2.3	193
722	Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995. Drug and Alcohol Dependence, 2000, 57, 247-254.	3.2	86
723	One year follow-up of cannabis dependence among long-term users in Sydney, Australia. Drug and Alcohol Dependence, 2000, 59, 309-318.	3.2	70
724	MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet, The, 2000, 355, 1818-1821.	13.7	86
725	Challenge of reducing drug-related deaths. Lancet, The, 2000, 356, 7-8.	13.7	15
726	Is Ultra-Rapid Opioid Detoxification a Viable Option in the Treatment of Opioid Dependence?. CNS Drugs, 2000, 14, 251-255.	5.9	5
727	Australia's mental health: an overview of the general population survey*. Australian and New Zealand Journal of Psychiatry, 2000, 34, 197-205.	2.3	43
728	Alcohol- and drug-use disorders in Australia: implications of the National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2000, 34, 206-213.	2.3	128
729	Opioid overdose mortality in Australia, 1964-1997: birth cohort trends. Medical Journal of Australia, 1999, 171, 34-37.	1.7	65
730	Is naltrexone a cure for heroin dependence?. Medical Journal of Australia, 1999, 171, 9-10.	1.7	11
731	The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. Addiction, 1999, 94, 1541-1550.	3.3	145
732	Prevalence of illicit drug use among youth: results from the Australian School Students' Alcohol and Drugs Survey. Australian and New Zealand Journal of Public Health, 1999, 23, 519-524.	1.8	49
733	HIV risk behaviour and prevention in prison: a bleach programme for inmates in NSW. Drug and Alcohol Review, 1999, 18, 139-143.	2.1	16
734	THE 1998 JAMES RANKIN ORATION: Reducing the toll of opioid overdose deaths in Australia. Drug and Alcohol Review, 1999, 18, 213-220.	2.1	21
735	Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug and Alcohol Dependence, 1999, 54, 155-161.	3.2	108
736	Role of maintenance treatment in opioid dependence. Lancet, The, 1999, 353, 221-226.	13.7	399
737	Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review, 1998, 17, 153-158.	2.1	75
738	Cohort trends in age of initiation to heroin use. Drug and Alcohol Review, 1998, 17, 289-297.	2.1	38

#	ARTICLE	IF	CITATIONS
739	Cannabis use and psychosis. Drug and Alcohol Review, 1998, 17, 433-444.	2.1	77
740	The respiratory risks of cannabis smoking. Addiction, 1998, 93, 1461-1463.	3.3	25
741	Jurisdictional trends in opioid overdose deaths, 1988-96. Australian and New Zealand Journal of Public Health, 1998, 22, 802-807.	1.8	8
742	A bleach program for inmates in NSW: an HIV prevention strategy. Australian and New Zealand Journal of Public Health, 1998, 22, 838-840.	1.8	26
743	The Decline in Alcohol Disorders with Age: Causes and Implications. Australasian Journal on Ageing, 1998, 17, 158-159.	0.9	1
744	Choosing a diagnostic cut-off for cannabis dependence. Addiction, 1998, 93, 1681-1692.	3.3	132
745	Long-term cannabis use: characteristics of users in an Australian rural area. Addiction, 1998, 93, 837-846.	3.3	176
746	Patterns and correlates of cannabis dependence among long-term users in an Australian rural area. Addiction, 1998, 93, 1149-1160.	3.3	49
747	An evaluation of Cloninger's typology of alcohol abuse. Addiction, 1998, 93, 1241-1249.	3.3	18
748	A mathematical model of HIV transmission in NSW prisons. Drug and Alcohol Dependence, 1998, 50, 197-202.	3.2	16
749	Trends in opiate overdose deaths in Australia 1979-1995. Drug and Alcohol Dependence, 1998, 52, 71-77.	3.2	102
750	The Development of an early Warning System to Detect Trends in Illicit Drug use in Australia: The Illicit Drug Reporting System. Addiction Research, 1998, 6, 97-113.	0.6	56
751	Adverse effects of cannabis. Lancet, The, 1998, 352, 1611-1616.	13.7	719
752	Factor Structure of Psychopathy Among Methadone Maintenance Patients. Journal of Personality Disorders, 1998, 12, 162-171.	1.4	13
753	Characteristics of Long-Term Cannabis Users in Sydney, Australia. European Addiction Research, 1998, 4, 190-197.	2.4	20
754	The Role of Legal Coercion in the Treatment of Offenders with Alcohol and Heroin Problems. Australian and New Zealand Journal of Criminology, 1997, 30, 103-120.	2.5	36
755	Comorbidity of mental disorders with substance misuse. British Journal of Psychiatry, 1997, 171, 4-5.	2.8	75
756	Long-term cannabis use and mental health. British Journal of Psychiatry, 1997, 171, 107-108.	2.8	55

#	ARTICLE	IF	CITATIONS
757	The alcohol withdrawal syndrome. Lancet, The, 1997, 349, 1897-1900.	13.7	177
758	Highs and lows. Lancet, The, 1997, 350, SIII1.	13.7	5
759	Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence, 1997, 46, 105-113.	3.2	71
760	Disability, outcome and case-mix in acute psychiatric in-patient units. British Journal of Psychiatry, 1997, 171, 242-246.	2.8	65
761	Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction, 1997, 92, 697-705.	3.3	37
762	The recent Australian debate about the prohibition on cannabis use. Addiction, 1997, 92, 1109-1116.	3.3	19
763	The distribution of naloxone to heroin users. Addiction, 1997, 92, 1195-1200.	3.3	93
764	Methadone maintenance and drug-related crime. Journal of Substance Abuse, 1997, 9, 15-25.	1.1	64
765	Rapid opiate detoxification treatment. Drug and Alcohol Review, 1997, 16, 325-327.	2.1	13
766	Transitions between routes of benzodiazepine administration among heroin users in Sydney. Addiction, 1997, 92, 697-706.	3.3	3
767	Evidence-based treatment for drug misuse: bridging the gap between aspiration and achievement. Addiction, 1997, 92, 373-374.	3.3	6
768	The recent Australian debate about the prohibition on cannabis use. Addiction, 1997, 92, 1109-1116.	3.3	1
769	The distribution of naloxone to heroin users. Addiction, 1997, 92, 1195-1200.	3.3	1
770	Are there two types of alcoholism?. Lancet, The, 1996, 348, 1258.	13.7	10
771	Are detoxification programmes effective?. Lancet, The, 1996, 347, 97-100.	13.7	181
772	Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence, 1996, 43, 191-198.	3.2	54
773	Methadone Maintenance Therapy for Opioid Dependence. CNS Drugs, 1996, 6, 440-449.	5.9	20
774	Hiv Risk Behaviour of Idus Before, During and After Imprisonment in New South Wales. Addiction Research, 1996, 4, 151-160.	0.6	42

#	ARTICLE	IF	CITATIONS
775	Is a syringe exchange feasible in a prison setting?. Medical Journal of Australia, 1996, 164, 508-508.	1.7	7
776	How can we reduce heroin "overdose" deaths?. Medical Journal of Australia, 1996, 164, 197-198.	1.7	14
777	Harm reduction as a focus for research. Drug and Alcohol Review, 1996, 15, 5-6.	2.1	3
778	Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-92: I. Illicit drug problems. Drug and Alcohol Review, 1996, 15, 127-132.	2.1	9
779	Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-92: II. Alcohol problems. Drug and Alcohol Review, 1996, 15, 133-136.	2.1	1
780	Correlates of the perceived health risks of marijuana use among Australian adults. Drug and Alcohol Review, 1996, 15, 137-143.	2.1	11
781	What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders?. Drug and Alcohol Review, 1996, 15, 157-170.	2.1	51
782	Benzodiazepine use among heroin users in Sydney: patterns of use, availability and procurement. Drug and Alcohol Review, 1996, 15, 237-243.	2.1	30
783	Prescription Drug Utilization Following Patient Co-Payment Changes in Australia. , 1996, 5, 385-392.		41
784	Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction, 1996, 91, 81-87.	3.3	64
785	Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction, 1996, 91, 405-411.	3.3	260
786	Overdose among heroin users in Sydney, Australia: II. Responses to overdose. Addiction, 1996, 91, 413-417.	3.3	69
787	Characteristics of women with alcohol and other drug problems: findings of an Australian national survey. Addiction, 1996, 91, 1141-1150.	3.3	73
788	Steering a course between the Charybdis of credulity and the Scylla of scepticism. Addiction, 1996, 91, 770-773.	3.3	0
789	Statistical questions. Addiction, 1996, 91, 1808-1809.	3.3	0
790	Changes in the public perceptions of the health benefits of alcohol use, 1989 to 1994. Australian and New Zealand Journal of Public Health, 1996, 20, 93-95.	1.8	16
791	The effectiveness and safety of methadone maintenance. Addiction, 1996, 91, 1727-1728.	3.3	11
792	Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction, 1996, 91, 405-411.	3.3	241

#	ARTICLE	IF	CITATIONS
793	Overdose among heroin users in Sydney, Australia: II. Responses to overdose. <i>Addiction</i> , 1996, 91, 413-417.	3.3	105
794	Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. <i>Addiction</i> , 1996, 91, 81-87.	3.3	79
795	Is there a role for contact tracing in preventing HIV transmission among injecting drug users?. <i>Addiction</i> , 1996, 91, 917-919.	3.3	3
796	Methadone maintenance reduces injecting in prison. <i>BMJ: British Medical Journal</i> , 1996, 312, 1162-1162.	2.3	59
797	Heroin overdose: the case for take-home naloxone. <i>BMJ: British Medical Journal</i> , 1996, 312, 1435-1436.	2.3	138
798	Variations in Prohibition: Harm Minimisation and Drug Wars in Australia and the United States. <i>Australian and New Zealand Journal of Criminology</i> , 1995, 28, 74-77.	2.5	1
799	Changes in the characteristics of clients admitted to an Australian therapeutic community, "The Buttery", 1980-92. <i>Drug and Alcohol Review</i> , 1995, 14, 125-129.	2.1	2
800	Making research more relevant to practice. <i>Drug and Alcohol Review</i> , 1995, 14, 149-150.	2.1	4
801	The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. <i>Addiction</i> , 1995, 90, 607-614.	3.3	762
802	Benzodiazepine use among injecting heroin users. <i>Medical Journal of Australia</i> , 1995, 162, 645-647.	1.7	78
803	Benzodiazepine prescribing in general practice: dispelling some myths. <i>Family Practice</i> , 1995, 12, 37-43.	1.9	31
804	Injecting and sexual risk-taking behaviour among regular amphetamine users. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 1995, 7, 19-26.	1.2	21
805	Levels and correlates of polydrug use among heroin users and regular amphetamine users. <i>Drug and Alcohol Dependence</i> , 1995, 39, 231-235.	3.2	164
806	Quitting smoking: estimation by meta-analysis of the rate of unaided smoking cessation. <i>Australian Journal of Public Health</i> , 1995, 19, 129-131.	0.2	76
807	A controlled trial of educational visiting to improve benzodiazepine prescribing in general practice. <i>Australian Journal of Public Health</i> , 1995, 19, 142-148.	0.2	36
808	The public health significance of cannabis use in Australia. <i>Australian Journal of Public Health</i> , 1995, 19, 235-242.	0.2	20
809	The effects of partial decriminalisation on cannabis use in South Australia, 1985 to 1993. <i>Australian Journal of Public Health</i> , 1995, 19, 281-287.	0.2	45
810	The AUDIT questionnaire: choosing a cut-off score. <i>Addiction</i> , 1995, 90, 1349-1356.	3.3	444

#	ARTICLE	IF	CITATIONS
811	Management and treatment efficacy of drug and alcohol problems: what do doctors believe?. <i>Addiction</i> , 1995, 90, 1357-1366.	3.3	49
812	Methadone maintenance treatment. <i>BMJ: British Medical Journal</i> , 1995, 310, 1408-1408.	2.3	2
813	Evidence of HIV transmission in an Australian prison. <i>Medical Journal of Australia</i> , 1994, 160, 734-734.	1.7	25
814	The Health and Psychological Effects of Cannabis Use. <i>Current Issues in Criminal Justice</i> , 1994, 6, 208-220.	1.4	16
815	Alcohol Use and Incarceration in a Police Lockup among Aboriginals in the Kimberley Region of Western Australia. <i>Australian and New Zealand Journal of Criminology</i> , 1994, 27, 57-73.	2.5	6
816	Recent developments in the study of behaviour phenotypes. <i>Journal of Intellectual & Developmental Disability</i> , 1994, 19, 275-279.	0.3	3
817	Predictors of increased mortality in elderly depressed patients. <i>International Journal of Geriatric Psychiatry</i> , 1994, 9, 219-227.	2.7	36
818	HIV risk-taking behaviour among amphetamine users in Sydney, Australia. <i>Addiction</i> , 1994, 89, 79-85.	3.3	46
819	Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. <i>Addiction</i> , 1994, 89, 211-217.	3.3	67
820	Predictors of injecting and injecting risk-taking behaviour among methadone maintenance clients. <i>Addiction</i> , 1994, 89, 311-316.	3.3	60
821	Transitions between routes of administration of regular amphetamine users. <i>Addiction</i> , 1994, 89, 1077-1083.	3.3	86
822	Value for money in addiction services. <i>Addiction</i> , 1994, 89, 920-921.	3.3	0
823	Meta-analytic review of the efficacy of smoking cessation interventions. <i>Drug and Alcohol Review</i> , 1994, 13, 157-170.	2.1	50
824	Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. <i>Drug and Alcohol Review</i> , 1994, 13, 277-284.	2.1	45
825	Geographical differences in risk-taking among Sydney methadone maintenance patients: a comparison of inner city and outer south western methadone maintenance patients. <i>Drug and Alcohol Review</i> , 1994, 13, 301-305.	2.1	6
826	A summary of recommendations for the management of opioid dependence: the quality assurance in the treatment of drug dependence project*. <i>Drug and Alcohol Review</i> , 1994, 13, 319-326.	2.1	2
827	The effectiveness of methadone maintenance treatment: an overview. <i>Drug and Alcohol Review</i> , 1994, 13, 327-336.	2.1	65
828	Prevalence, symptoms and correlates of antisocial personality disorder among methadone maintenance clients. <i>Drug and Alcohol Dependence</i> , 1994, 34, 253-257.	3.2	49

#	ARTICLE	IF	CITATIONS
829	Methadone maintenance treatment in prisons: The new South Wales experience. <i>Psychiatry, Psychology and Law</i> , 1994, 1, 33-44.	1.2	1
830	Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. <i>Gastroenterology</i> , 1994, 106, 742-748.	1.3	28
831	When is a Behavioural Phenotype Not a Phenotype?. <i>Developmental Medicine and Child Neurology</i> , 1994, 36, 467-470.	2.1	14
832	Fortnightly Review: Methadone maintenance treatment in opiate dependence: a review. <i>BMJ: British Medical Journal</i> , 1994, 309, 997-1001.	2.3	345
833	The structure and correlates of alcohol dependence: WHO collaborative project on the early detection of persons with harmful alcohol consumption-III. <i>Addiction</i> , 1993, 88, 1627-1636.	3.3	47
834	Patterns of drug use and risk-taking among injecting amphetamine and opioid drug users in Sydney, Australia. <i>Addiction</i> , 1993, 88, 509-516.	3.3	36
835	Alcohol-related problems among Aboriginal drinkers in the Kimberley region of Western Australia. <i>Addiction</i> , 1993, 88, 1091-1100.	3.3	6
836	Perfectionism in the therapeutic appraisal of methadone maintenance. <i>Addiction</i> , 1993, 88, 1181-1182.	3.3	6
837	Methadone maintenance treatment in prisons: The New South Wales Experience. <i>Drug and Alcohol Review</i> , 1993, 12, 193-203.	2.1	27
838	A comparison of a specialist women's alcohol and other drug treatment service with two traditional mixed-sex services: client characteristics and treatment outcome. <i>Drug and Alcohol Dependence</i> , 1993, 32, 81-92.	3.2	84
839	Crime and drug use among applicants for methadone maintenance. <i>Drug and Alcohol Dependence</i> , 1993, 31, 123-129.	3.2	79
840	Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. <i>Drug and Alcohol Dependence</i> , 1993, 34, 67-70.	3.2	102
841	Illicit amphetamine use as a public health problem in Australia. <i>Medical Journal of Australia</i> , 1993, 159, 643-644.	1.7	7
842	Anxiety, Depression and HIV Related Symptomatology across the Spectrum of HIV Disease. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 560-566.	2.3	42
843	The Australian Debate about the Legalization of Heroin and other Illicit Drugs, 1988-1991. <i>Journal of Drug Issues</i> , 1992, 22, 563-577.	1.2	7
844	Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. <i>Drug and Alcohol Dependence</i> , 1992, 31, 31-36.	3.2	77
845	Benzodiazepine prescribing and injecting drug users. <i>Medical Journal of Australia</i> , 1992, 157, 573-574.	1.7	0
846	Patterns of alcohol consumption in the Kimberley Aboriginal population. <i>Medical Journal of Australia</i> , 1992, 156, 764-768.	1.7	20

#	ARTICLE	IF	CITATIONS
847	Methadone maintenance and the human immunodeficiency virus: current issues in treatment and research. <i>Addiction</i> , 1992, 87, 447-453.	3.3	40
848	A comparison of predictors of treatment drop-out of women seeking drug and alcohol treatment in a specialist women's and two traditional mixed-sex treatment services. <i>Addiction</i> , 1992, 87, 883-890.	3.3	65
849	Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. <i>Addiction</i> , 1992, 87, 1161-1172.	3.3	340
850	Changes in criminal activity after entering methadone maintenance. <i>Addiction</i> , 1992, 87, 251-258.	3.3	73
851	Development and validation of a multidimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. <i>Addiction</i> , 1992, 87, 733-742.	3.3	381
852	Development of a short "readiness to change" questionnaire for use in brief, opportunistic interventions among excessive drinkers. <i>Addiction</i> , 1992, 87, 743-754.	3.3	665
853	Prevalence and predictors of psychopathology among opioid users. <i>Addiction</i> , 1992, 87, 771-776.	3.3	46
854	A comparison of women seeking drug and alcohol treatment in a specialist women's and two traditional mixed-sex treatment services. <i>Addiction</i> , 1992, 87, 1293-1302.	3.3	83
855	Alcohol and recreational drug use by HIV-seropositive homosexual men. <i>Drug and Alcohol Review</i> , 1992, 11, 355-362.	2.1	3
856	Behavior phenotype of the fragile X syndrome. <i>American Journal of Medical Genetics Part A</i> , 1992, 43, 56-60.	2.4	17
857	The public perception of the risks and benefits of alcohol consumption. <i>Australian Journal of Public Health</i> , 1992, 16, 38-42.	0.2	21
858	Estimates of the number of injecting drug users in a defined area. <i>Australian Journal of Public Health</i> , 1992, 16, 232-237.	0.2	12
859	Issue of statistical power in comparative evaluations of minimal and intensive controlled drinking interventions. <i>Addictive Behaviors</i> , 1991, 16, 83-87.	3.0	11
860	The characteristics of cocaine users among young adults in Sydney. <i>Medical Journal of Australia</i> , 1991, 155, 11-14.	1.7	16
861	The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. <i>Aids</i> , 1991, 5, 181-186.	2.2	234
862	Estimating drug consumption in opioid users: reliability and validity of a "recent use" episodes method. <i>British Journal of Addiction</i> , 1991, 86, 1311-1316.	0.1	78
863	Calculating standard drink units: international comparisons. <i>Addiction</i> , 1991, 86, 43-47.	3.3	133
864	Issues in the assessment of outcome in depressive illness in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 1991, 6, 269-277.	2.7	8

#	ARTICLE	IF	CITATIONS
865	Hyperactivity and the Fragile X Syndrome. <i>Journal of Abnormal Child Psychology</i> , 1991, 19, 253-262.	3.5	26
866	Alpha 1 antitrypsin phenotypes and alcoholic pancreatitis.. <i>Gut</i> , 1991, 32, 945-948.	12.1	30
867	Depression Sub-Typing: Unitary, Binary or Arbitrary?. <i>Australian and New Zealand Journal of Psychiatry</i> , 1991, 25, 63-76.	2.3	17
868	Public attitudes towards alcohol control policies. <i>Australian Journal of Public Health</i> , 1991, 15, 301-306.	0.2	18
869	Drug use, injecting practices and sexual behaviour of opioid users in Sydney, Australia. <i>Addiction</i> , 1990, 85, 1603-1609.	3.3	58
870	The drug market position of cocaine among young adults in Sydney. <i>Addiction</i> , 1990, 85, 891-897.	3.3	11
871	Quantification of physical illness in psychiatric research in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 1990, 5, 161-170.	2.7	87
872	On Doing the "Impossible": Inferring that a Putative Causal Relationship does not Exist. <i>Australian and New Zealand Journal of Psychiatry</i> , 1990, 24, 217-226.	2.3	10
873	The injecting and sexual behaviour of intravenous drug users in Sydney. <i>Medical Journal of Australia</i> , 1990, 152, 446-446.	1.7	2
874	Life Events, Life Difficulties and Confiding Relationships in the Depressed Elderly. <i>British Journal of Psychiatry</i> , 1989, 155, 787-792.	2.8	62
875	Behaviour Completion Mechanisms, Anxiety and Agoraphobia. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 373-378.	2.3	0
876	The Limitations of Multivariate Statistical Methods in the Mensuration of Human Misery. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 503-511.	2.3	1
877	The logic of a controversy: The case of agent orange in Australia. <i>Social Science and Medicine</i> , 1989, 29, 537-544.	3.8	11
878	Autism is not associated with the Fragile X syndrome. <i>American Journal of Medical Genetics Part A</i> , 1989, 34, 187-193.	2.4	64
879	"Repetition strain injury"™: An Australian epidemic of upper limb pain. <i>Social Science and Medicine</i> , 1988, 27, 645-649.	3.8	42
880	Can Localised Brain Impairment Be Simulated on Neuropsychological Test Profiles?. <i>Australian and New Zealand Journal of Psychiatry</i> , 1987, 21, 87-93.	2.3	31
881	A Simplified Logic of Causal Inference. <i>Australian and New Zealand Journal of Psychiatry</i> , 1987, 21, 507-513.	2.3	28
882	DISEASE COSTS AND THE ALLOCATION OF HEALTH RESOURCES. <i>Bioethics</i> , 1987, 1, 211-225.	1.4	3

#	ARTICLE	IF	CITATIONS
883	Comparisons of psychological and social factors in patients with chronic oro-facial pain and dental phobic disorders*. Australian Dental Journal, 1987, 32, 331-335.	1.5	18
884	The Agent Orange controversy. Medical Journal of Australia, 1987, 146, 453-454.	1.7	0
885	Social class and survival on the S.S. Titanic. Social Science and Medicine, 1986, 22, 687-690.	3.8	26
886	The Agent Orange controversy after the Evatt Royal Commission. Medical Journal of Australia, 1986, 145, 219-225.	1.7	10
887	Simultaneous Multiple Comparison Procedures in Psychiatric Research. Australian and New Zealand Journal of Psychiatry, 1986, 20, 46-54.	2.3	18
888	Statistical Power in Psychiatric Research. Australian and New Zealand Journal of Psychiatry, 1986, 20, 189-200.	2.3	27
889	Simultaneous Multiple Comparison Procedures for Categorical Data. Australian and New Zealand Journal of Psychiatry, 1986, 20, 350-359.	2.3	19
890	Does Depressive Illness in the Elderly Have a Poor Prognosis?. Australian and New Zealand Journal of Psychiatry, 1986, 20, 422-427.	2.3	17
891	The Problem of Multiple Inference in Psychiatric Research. Australian and New Zealand Journal of Psychiatry, 1985, 19, 265-274.	2.3	51
892	The Costs of Schizophrenia. Australian and New Zealand Journal of Psychiatry, 1985, 19, 3-5.	2.3	9
893	Early Sensory-Perceptual Changes in Huntington's Disease. Australian and New Zealand Journal of Psychiatry, 1985, 19, 384-389.	2.3	9
894	Do Vietnam Veterans Suffer from Toxic Neurasthenia?. Australian and New Zealand Journal of Psychiatry, 1985, 19, 19-29.	2.3	11
895	THE AGENT ORANGE CONTROVERSY IN AUSTRALIA: A CONTRIBUTION TO THE DEBATE*. Community Health Studies, 1985, 9, 109-119.	0.0	5
896	Psychotropic Drug Prescribing in an Australian General Practice. Family Practice, 1984, 1, 106-112.	1.9	6
897	Obesity, Alcohol Consumption and Blood Pressure in Australian Men and Women The National Heart Foundation of Australia Risk Factor Prevalence Study. Journal of Hypertension, 1984, 2, 85-91.	0.5	165
898	The incidence of schizophrenia in New South Wales, Australia.. Acta Psychiatrica Scandinavica, 1984, 70, 220-227.	4.5	18
899	Psychiatric Impairment, Physical Health and Work Values among Unemployed and Apprenticed Young Men. Australian and New Zealand Journal of Psychiatry, 1983, 17, 335-340.	2.3	23
900	A Survey of Practising Psychiatrists' Views on the Treatment of Agoraphobia. Australian and New Zealand Journal of Psychiatry, 1982, 16, 225-233.	2.3	11

#	ARTICLE	IF	CITATIONS
901	Psychological Approaches to the Evaluation of Chronic Pain Patients. Australian and New Zealand Journal of Psychiatry, 1982, 16, 3-9.	2.3	7
902	Pain and laterality in a British pain clinic sample. Pain, 1982, 14, 63-66.	4.2	17
903	Communication to the editor. Journal of Psychosomatic Research, 1982, 26, 99-100.	2.6	3
904	On "the lateralization of pain". Pain, 1981, 10, 337-351.	4.2	33
905	On "Ratio scales of sensory and affective verbal pain descriptors". Pain, 1981, 11, 101-107.	4.2	20
906	The Case of William Chidley: A Study in Psychiatry, Morality and Lunacy Law. Australian and New Zealand Journal of Psychiatry, 1980, 14, 133-139.	2.3	5
907	Schizophrenia secondary to cannabis use. , 0, , 169-178.		0
908	Substance Use and Mental Health in Longitudinal Perspective. , 0, , 43-51.		20
909	Drug use and drug dependence. , 0, , 230-249.		1
910	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
911	The public health implications of genetic research on addiction. , 0, , 155-173.		0
912	The implications of genetic research on alcohol dependence for prevention and treatment. , 0, , 16-30.		1
913	Are addicted individuals responsible for their behaviour?. , 0, , 146-167.		0
914	Addictions. , 0, , .		1
915	Drug Addiction, Society and Ethics. , 0, , 639-645.		1
916	The iCannToolkit: A consensus-based, flexible framework for measuring contemporary cannabis use. Addiction, 0, , .	3.3	1